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resumo 
 
 
O osteossarcoma é o tipo mais comum de tumor maligno do osso. Esta 
doença apresenta uma elevada incidência em crianças e adolescentes. 
Adicionalmente, metástases, ocorrendo principalmente nos pulmões, afectam 
uma percentagem considerável dos pacientes com osteossarcoma. Os 
tratamentos actuais incluem ressecção cirúrgica, quimioterapia e radioterapia, 
mas os pacientes com osteossarcoma apresentam uma baixa capacidade de 
resposta a estas opções de tratamento. Assim, é urgente desenvolver novas 
abordagens de tratamento. O sulforafano é um fitocomposto que exibe 
actividade quimiopreventiva e quimioterápica. Numerosos estudos têm 
demonstrado que o sulforafano modula muitos eventos associados ao cancro, 
como susceptibilidade a agentes carcinogénicos, ciclo celular, apoptose, 
angiogénese e metastização. Apesar de bem caracterizados em diversos 
tumores, os efeitos do sulforafano são ainda insuficientemente conhecidos no 
osteossarcoma, assim como o mecanismo de acção subjacente. O objectivo 
desta dissertação foi avaliar os potenciais efeitos citostático e apoptótico do 
sulforafano e revelar o mecanismo de acção por trás destes efeitos. Para isso, 
a linha celular de osteossarcoma humano MG-63 foi exposta a sulforafano (no 
intervalo de 0 a 20 µM) durante 24 e 48 h. Parâmetros como confluência, 
morfologia celular, viabilidade celular, ciclo celular, clastogenicidade, apoptose, 
actividade específica de caspases e expressão de genes associados ao ciclo 
celular foram analisados após o tratamento com sulforafano. As culturas 
expostas ao sulforafano apresentaram uma diminuição da confluência, 
acompanhada de alterações na morfologia celular. O sulforafano também 
induziu uma diminuição da viabilidade celular dependente da dose e do tempo 
de exposição que pode ser explicada pelo aumento de células apoptóticas e 
por citostaticidade com bloqueio na fase G2/M. Este bloqueio do ciclo celular foi 
mediado por Chk2, pela sub-expressão de CDC25C e, provavelmente, pela 
sub-expressão de CCNB1, assim como de CDK2. Um efeito clastogénico foi 
também detectado após 48 h de tratamento com sulforafano. Estes dados 
sugerem que o sulforafano deve ser considerado um candidato a agente 
quimioterápico no tratamento de osteossarcoma, embora sejam necessários 
mais estudos para lançar luz sobre vias de sinalização moduladas pelo 
sulforafano, assim como sobre a possível citotoxicidade deste fitocomposto em 
osteoblastos normais.     
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abstract 
 
Osteosarcoma is the most common type of malignant bone tumor. This disease 
shows high incidence in children and adolescents. Additionally, metastases 
occurring mainly at the lungs affect a considerable percentage of osteosarcoma 
patients. Current treatments include surgical resection, chemotherapy, and 
radiotherapy, but osteosarcoma patients show poor responsiveness to these 
treatment options. Thus, it is urgent to develop novel treatment approaches. 
Sulforaphane is a phytochemical that displays chemopreventive and 
chemotherapeutic activity. Many studies have been shown that sulforaphane 
modulates many cancer-related events, as susceptibility to carcinogenic 
agents, cell cycle, apoptosis, angiogenesis, and metastasis. Although well 
characterized in several tumors, the effects of sulforaphane are still poorly 
understood in osteosarcoma, as well as the underlying mechanism of action. 
The aim of this dissertation was to evaluate the potential cytostatic and 
apoptotic effects of sulforaphane and to unveil the mechanism of action behind 
these effects. In order to do that, the human osteosarcoma cell line MG-63 was 
exposed to sulforaphane (in the 0 to 20 µM range) for 24 and 48 h. Parameters 
as confluence, cell morphology, cell viability, cell cycle, clastogenicity, 
apoptosis, caspase specific activity, and expression of cell cycle-related genes 
were analyzed after sulforaphane treatment. Cultures exposed to sulforaphane 
showed a decrease in confluence, accompanied by alterations in cell 
morphology. Sulforaphane also induced a dose- and time-dependent 
impairment of cell viability, which can be explained by an increase of apoptotic 
cells and cytostaticity with G2/M phase arrest. This cell cycle blockage was 
mediated by Chk2 and CDC25C downregulation, and probably CCNB1 as well 
as CDK2 downregulation. A clastogenic effect was also detected after 48 h of 
sulforaphane treatment. These data suggest that sulforaphane should be 
considered as a chemotherapeutic agent candidate in osteosarcoma treatment, 
although more studies are needed to shed insight on signaling pathways 
modulated by sulforaphane, as well as the possible cytotoxicity of this 
phytochemical on normal osteoblasts.       
 
 
 Part of the work described within this dissertation has been submitted for publication in 
Toxicology and Applied Pharmacology as part of the manuscript Remédios, C., Costa, M., 
Pinto, P., Pinho, F., Pedrosa, T., Pinho, S., Rosário, F., Ferreira de Oliveira, J.M.P., 
Oliveira, H. and Santos, C. (2012) Sulforaphane-induced DNA Damage in Osteosarcoma 
Cells: A Correlation with Oxidative Stress, Cell Cycle Arrest and Apoptosis. 
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I. INTRODUCTION 
 
1.1. Cancer 
1.1.1 General considerations about cancer 
Cancer is a major burden worldwide. Economically developed countries present overall 
cancer incidence rates twice as high as the ones found in developing countries (Jemal et 
al., 2011), mainly due to the Western lifestyle. According to the American Cancer Society, 
it is estimated that 1,638,910 men and women will be diagnosed with cancer and 577,190 
men and women will die of cancer in the United States in 2012, being these rates slightly 
higher for men than for women and with lung, colorectal, breast, and prostate cancers 
accounting for the largest numbers of new cases and deaths (Siegel et al., 2012). In 
Europe, cancer was listed as the second most common cause of death after cardiovascular 
diseases (OECD, 2012) with approximately 3.2 million estimated new cases and 1.7 
million estimated deaths in 2008 (Ferlay et al., 2010). Recent data project 1,283,101 cancer 
deaths to occur in Europe during the current year, with lung (262,250), colorectal 
(163,106), breast (88,101), and prostate (69,960) cancers as the main causes (Malvezzi et 
al., 2012), similarly to the United States. 
From a simplistic point of view, cancer can be defined as a group of diseases in which 
abnormal cells proliferate in an uncontrolled manner and spread to other tissues. However, 
during the past few decades, an immense body of knowledge evidenced the inherent 
complexities of cancer, but fortunately also unveiled its characteristics and the underlying 
molecular mechanisms.    
The etiological factors of cancer vary considerably from case to case. Chemical agents, 
lifestyle (e.g., diet, obesity, tobacco smoke, alcohol consumption), infections, radiation, 
genetic problems, and hormones are some of the factors already proved to correlate with 
carcinogenesis (Langeberg et al., 2007; Khan and Shrivastava, 2010; Khan et al., 2010; 
Vahakangas, 2011). However, the general established conception is that cancer results 
from cumulative genomic alterations that lead to atypical RNA and protein profiles, which 
INTRODUCTION 
 
 2 
in the end originate the abnormal cancer phenotype. Such alterations are often found in 
genes that in the cancer scenario behave as either tumor suppressors or oncogenes (Hahn 
and Weinberg, 2002). The range of cancer-inducing genomic changes is vast, yielding 
from intragenic mutations to aneuploidy events. Loss of function of tumor suppressors is 
usually directly or indirectly related with intragenic mutations (Malkin et al., 1990) and 
deletions or allelic loss (Wei et al., 1999; Yoshimoto et al., 2007) of the corresponding 
genes. In the case of oncogenes, mutations (Akagi et al., 2007), chromosomal 
translocations (MacKenzie et al., 1993), and genomic amplifications (Birkeland et al., 
2012) are the three major events explaining gain of function. In recent years, epigenetic 
alterations, heritable alterations in gene expression without changes in the primary DNA 
sequence (Sadikovic et al., 2008a), were also found to be main contributors for cancer 
development. Variations in the DNA methylation profile of genes or gene promoters are 
common drivers of carcinogenesis (Futscher et al., 2004), but histone modifications 
(Kondo et al., 2007) and changes in nucleosome positioning (Medina and Sanchez-
Cespedes, 2008) are important players in that process, as well.      
Based on these and other findings of the past decades and on the assumption that the 
molecular machinery owned by mammalian cells is equable, Douglas Hanahan and Robert 
A. Weinberg suggested that most – if not all – human cancers share the same functional 
capabilities that allow cancer cells to survive, proliferate, and disseminate (Hanahan and 
Weinberg, 2000). The six hallmarks of cancer proposed by these authors in 2000 include: 
 
1) Self-sufficiency in growth signals. In order to grow and proliferate, normal cells 
require the binding of growth signals to transmembrane receptors and the subsequent 
activation of intracellular signal transduction cascades that culminate in a pro-growth 
cellular response. Tumor cells can reduce the dependency on exogenous signals by 
different means, such as producing their own growth signals (e.g., platelet-derived growth 
factor (PDGF) (Furuhashi et al., 2004)) and overexpressing growth signal receptors (e.g., 
human epidermal growth factor receptor 2 (HER2) (Loi et al., 2011)), thus breaching 
homeostasis and achieving abnormal growth rates. 
2) Insensitivity to antigrowth signals. Besides growth signals, a normal cell is also 
exposed to antigrowth signals from the environment. As the name suggests, these 
molecules act as antiproliferative signals, inducing either a quiescent state or cell 
differentiation. Deregulation of proteins involved in signaling pathways transducing 
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antigrowth signals is often found in cancers and usually such proteins are intimately related 
with cell cycle progression. One example is retinoblastoma-associated protein (Rb), a 
major transducer of antigrowth signals that inhibits transcription factors, preventing cell 
cycle progression (Jonsson et al., 2012).        
3) Evasion of apoptosis. Together with proliferation rates, the life span of a tumor cell 
is an important determinant of the overall tumor progression. Apoptosis is the cell death 
pathway commonly activated to maintain tissue homeostasis, but cancer cells seem to be 
resistant to this mechanism. Alterations in apoptotic mediators are extremely abundant in 
cancers. Amongst such mediators, p53, a tumor suppressor also known as “guardian of the 
genome” due to its function when DNA damage occurs, is frequently found to suffer 
different deregulations (Malkin et al., 1990; Pogribny and James, 2002), preventing 
activation of the apoptotic cascade.  
4) Limitless replicative potential. Within a normal tissue, cells undergo a finite 
number of replications, after which they become senescent. This event can be explained by 
the existence of telomeres, thousands of short nucleotide sequence repeats protecting the 
ends of chromosomes. During each replication cycle, chromosomes lose telomeric DNA, 
resulting in a progressive telomere shortening throughout cell life that eventually leads to 
death (Londono-Vallejo and Wellinger, 2012). However, tumor cells appear to undergo 
unlimited replications, thanks to the expression of functional telomerase, the DNA 
polymerase that adds DNA sequence repeats to the 3’ ends of chromosomal DNA for 
telomere maintenance, which is almost absent in normal cells (Chen and Chen, 2011).  
5) Sustained angiogenesis. A critical step in tumor progression is the maintenance of 
the expansion rate. As the tumor becomes larger, the inner cells of the tumor mass 
experience unfavorable conditions and often die due to the lack of blood supply that 
enables delivery of nutrients and oxygen, as well as removal of waste products and carbon 
dioxide. In order to surpass short blood supply and to continue to grow, tumors must 
activate an “angiogenic switch” and induce angiogenesis, the process of blood vessel 
formation from quiescent blood vessels (Hanahan and Folkman, 1996). Under hypoxic 
conditions, hypoxia-inducible factor 1 (HIF-1), an heterodimer possessing an oxygen 
sensor subunit (HIF-1α), is responsible for prompting angiogenesis in several human 
cancers via transcription factor activity that results in overexpression of vascular 
endothelial growth factor (VEGF); VEGF is a major growth signal that binds to tyrosine 
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kinase receptors of endothelial cells, stimulating proliferation and generation of new blood 
vessels (Semenza, 2000). Both oxygen deprivation (Shweiki et al., 1992) and genetic 
alterations causing increased activity of HIF-1 (Maxwell et al., 1999; Ravi et al., 2000) 
seem to be two reasonable mechanisms behind angiogenesis in tumors.  
6) Tissue invasion and metastasis. This pivotal step in tumor development comprises 
the escape of tumor cells from the initial tumor mass, the invasion of other tissues 
(adjacent or distant), and the settlement of new colonies: metastatic or secondary tumors. 
The fifth hallmark is intrinsically connected with the metastatic process providing the main 
route for primary tumor cells evasion and displacement (Zetter, 1998). Cancer cells that 
acquired this capability often present loss of molecules mediating cell-cell adhesion (e.g., 
cadherins (Yoshida et al., 2001)). Other feature that enhances the invasive potential of 
tumor cells is the upregulation of matrix metalloproteinases (MMPs) (Lafleur et al., 2005; 
Kryczka et al., 2012), zinc-dependent extracellular matrix-degrading proteases. 
 
These functional capabilities are attained through a multistep tumorigenic process driven 
by the accumulation of genomic alterations, but one particular lesion may give rise to 
several capabilities at the same time (Hanahan and Weinberg, 2000).  
Four years later, Dunn, Old, and Schreiber proposed a seventh hallmark of cancer: 
avoidance of immunosurveillance (Dunn et al., 2004). In truth, highly immunogenic cancer 
cells can be detected and destroyed by the immune system, but the remaining ones are 
spared due to their weak immunogenic phenotype (immunoediting) and ability to 
dismantle components of both arms of the immune system (Dunn et al., 2004). 
In 2008, Guido Kroemer and Jacques Pouyssegur discussed the complex interactions 
between these seven hallmarks and tumor cell metabolism (Kroemer and Pouyssegur, 
2008). Many tumor cells undergo a “metabolic switch” in which their energy production is 
highly limited to glycolysis instead of mitochondrial oxidative phosphorylation even in 
normoxic conditions, a concept brought up by Otto Warburg many decades ago (Warburg, 
1956). Underlying this metabolic reprogramming is, among others, the upregulation of 
glucose transporters and enzymes of the glycolytic pathway (Jones and Thompson, 2009).  
Last year, Hanahan and Weinberg (2011) revisited their former list of hallmarks, 
highlighted the importance of tumor microenvironment in the carcinogenic process, 
included the mechanisms that have been discussed in the meantime, and considered new 
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hallmarks: genome instability and mutation, and tumor-promoting inflammation. The first 
refers to the acceleration in the accumulation of mutations by the cancer cell through a 
variety of mechanisms, such as the collapse of DNA damage sensors or DNA damage 
repairing machinery (Jackson and Bartek, 2009). The second, explores the ability of tumor 
cells to induce an inflammatory response in the tumor microenvironment, that promotes 
several steps of the carcinogenic process; innate immune cells play here an important role 
by releasing reactive oxygen species (ROS) and growth factors in the vicinity of the tumor 
(Qian and Pollard, 2010).  
Figure 1 illustrates the establishment of cancer hallmarks throughout the years as result of 
the incessant research on this subject.  
 
 
 
Figure 1. Cancer hallmarks established over the past decade. The 2011 up-to-date Hanahan and 
Weinberg’s scheme enclosing: the six acquired hallmarks of cancer cells (sustaining proliferative signaling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and 
activating invasion and metastasis) initially proposed by these authors in 2000; a seventh hallmark (avoiding 
immune destruction) recommended by Dunn and colleagues in 2004; the deregulated cellular energetics 
integrated by Kroemer and Pouyssegur in 2008; and two enabling characteristics (genome instability and 
mutation, and tumor-promoting inflammation) added by Hanahan and Weinberg in 2011. Adapted from 
Hanahan and Weinberg (2011). 
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1.1.2. Target mechanisms in cancer therapy 
The compelling body of research and knowledge accomplished in the past decades lead to 
a better understanding of carcinogenesis and the molecular mechanisms behind it, and 
concomitantly to the progress in identifying novel targets for mechanism-based targeted 
therapies in human cancers. These therapies target specific key molecules that are involved 
in aberrant signaling pathways, thus modulating proliferation, differentiation, and death of 
cancer cells (Cattley and Radinsky, 2004). Such specificity can bring advantages for cancer 
treatment, as it is expected to show more effective results in cancer cells than current 
treatment approaches and less harmful effects on normal cells. As is already apparent, the 
mechanisms underlying cancer hallmarks offer attractive therapeutic targets and, in the 
next sections, two of these mechanisms – cell cycle and apoptosis – will be described in 
more detail and some targeted therapies exploiting them will be enumerated. 
1.1.2.1. Cell cycle 
Mammalian cell proliferation consists of repeated cell cycles that are divided in two main 
stages: mitosis (M), the process of nuclear division, and interphase, the period from the end 
of one mitosis to the beginning of the next one. Mitosis is subdivided in prophase, 
metaphase, anaphase, and telophase, whereas interphase comprises G1 (growth phase), S 
(DNA synthesis phase), and G2 (gap phase) phases (Norbury and Nurse, 1992). Non-
proliferating cells, which accounts for the majority of cells in the human body, enter a 
quiescent state at G1 that prevents further divisions – the G0 phase. As many other 
processes, cell cycle is strongly regulated by a wide number of proteins.  
Progression through the cell cycle is controlled by active protein kinase complexes, 
composed of a catalytic cyclin-dependent kinase (CDK, a family of serine/threonine 
protein kinases) and a regulatory cyclin. Throughout the cell cycle, CDK protein levels 
remain steady, but cyclin protein levels oscillate due to cyclic synthesis and degradation, 
leading to a periodically activation of CDKs (Pines, 1995). Consequently, CDKs are 
sequentially activated by specific cyclins during different phases, inducing cell cycle 
progression by phosphorylation of downstream proteins (Figure 2).  
CDK activity can also be counteracted by CDK inhibitors (CKIs) from two distinct 
families: Cip/Kip (for CDK interacting protein/kinase inhibitor protein), which includes 
p21Cip1, p27Kip1, p57Kip2; and Ink4 (for inhibitor of cyclin-dependent kinase 4 (Cdk4)), that 
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Figure 2. General scheme of the main cell cycle phases of mammalian cells and its key regulators. The 
specific CDK/cyclin associations required in each cell cycle phase and the CKIs that negatively regulate the 
main drivers of cell cycle progression. Adapted from Fuster et al. (2010).       
 
 
comprises p16Ink4a, p15Ink4b, p18Ink4c, p19Ink4d. The Cip/Kip proteins interact with and 
inhibit various CDK/cyclin complexes (Harper et al., 1995), whereas Ink4 proteins 
specifically bind to G1 CDKs, preventing their association with cyclin D (Carnero and 
Hannon, 1998) (Figure 2). In turn, CKIs are regulated by different internal and external 
signals. For instance, p21Cip1 expression is transcriptionally activated by the tumor 
suppressor p53 when DNA damage is detected (el-Deiry et al., 1993) and the expression 
and activation of p15Ink4b and p27Kip1, respectively, are influenced by transforming growth 
factor β (TGF-β) (Reynisdottir et al., 1995). 
In addition, CDK activity is regulated by phosphorylation/dephosphorylation on conserved 
threonine and tyrosine residues. For example, Wee1-like protein kinase (Wee1) and 
membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (Myt1) 
inactivate cyclin-dependent kinase 1 (Cdk1) by tyrosine-15 and/or threonine-14 
phosphorylation, and dephosphorylation of these sites is required for re-establishment of 
Cdk1 activity, which is mediated by phosphatases of the cell division cycle 25 (Cdc25) 
family (Medema and Macurek, 2012). Besides these molecules, others involved in 
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different signaling pathways (e.g., PI3K/Akt/mTOR pathway) can interact and modulate 
the cell cycle machinery.   
Investigation of cell cycle deregulations in the cancer context resulted in the development 
of some agents that target components of these pathways. Alvocidib is a small molecule 
that inhibits CDKs, inducing cell cycle arrest (Lee and Sicinski, 2006). NVP-BEZ235, an 
imidazo [4,5-c] quinoline derivative, induces G1 arrest by targeting the ATP-binding cleft 
of PI3K (for phosphatidylinositol 3-kinase) and mTOR (for mammalian target of 
rapamycin), whose activity is frequently altered in human cancer cells (Maira et al., 2008).    
1.1.2.2. Apoptosis 
Apoptosis, also known as programmed cell death, is a controlled type of cell death that 
plays an important role in tissue homeostasis. This process occurs in physiological 
conditions (e.g., embryonic development, normal cell turnover), but also as a response to 
pathological conditions (e.g., immune reactions) and cell injuries (e.g., radiation, hypoxia, 
harmful chemical agents) (Norbury and Hickson, 2001). Apoptosis is generally 
characterized by distinct morphological and biochemical characteristics. These hallmarks 
of apoptosis include expression of phosphatidylserine (PS) in the outer layer of the cell 
membrane, cell shrinkage, retraction of pseudopods, rounding up of the cell, membrane 
blebbing, ultrastructural modification of cytoplasmic organelles, chromatin condensation, 
DNA fragmentation, and loss of membrane integrity (Kroemer et al., 2005). At the end of 
the apoptotic process, the cellular content is enclosed into apoptotic bodies (“budding”), 
which are subsequently engulfed and degraded by phagocytic cells. Due to the restriction 
of the cellular constituents in apoptotic bodies, the rapid phagocytosis of apoptotic remains 
by surrounding cells and the absence of anti-inflammatory cytokines production by the 
latter cells, apoptosis is in essence not associated with inflammatory reactions (Kurosaka et 
al., 2003). Another feature of apoptosis is the activation of a group of enzymes belonging 
to the caspase (cysteine-aspartic acid protease) family that function as initiators and 
executioners of the apoptotic process (Lavrik et al., 2005). The activation of caspases can 
occur through two major pathways (Figure 3).  
The extrinsic or death receptor pathway is triggered when external signals bind to surface 
cell death receptors (e.g., tumor necrosis factor (TNF), Fas ligand (FasL), and TNF-related 
apoptosis-inducing ligand (TRAIL) bind to TNF receptors, TNF receptor superfamily 
member 6 (Fas), and TRAIL receptors, respectively) (Hengartner, 2001). Then, the 
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Figure 3. The intrinsic and extrinsic pathways to caspase activation in apoptosis. Activation of caspase 9 
by apoptosome complex and caspase 8 by DISC complex as a result of the triggering of mitochondrial and 
death receptor apoptotic pathways, respectively. The initiator caspases 8 and 9 cleave procaspase 3, leading 
to the activation of an executioner caspase cascade that ends in apoptosis. Members of the Bcl-2 family 
modulate apoptosis through the control of mitochondrial Cyt c release. Extracted from MacFarlane and 
Williams (2004).    
 
 
intracellular domain of death receptors recruits adapter proteins, such as TNF receptor-
associated death domain (TRADD) or Fas-associated death domain (FADD), as well as 
procaspase 8, forming a ligand-receptor-adapter protein complex, named death-inducing 
signaling complex (DISC), that activates the initiator caspase 8 (Schneider and Tschopp, 
2000).  
On the other hand, the intrinsic or mitochondrial pathway integrates various intracellular 
signals (e.g., irreparable DNA damage, hypoxia, severe oxidative stress) that cause 
mitochondrial permeability and release of pro-apoptotic molecules, such as cytochrome c 
(Cyt c) into the cytoplasm. Once released, Cyt c binds to apoptotic protease-activating 
factor 1 (Apaf-1), which in turn recruits procaspase 9, resulting in the formation of the 
apoptosome complex and activation of the initiator caspase 9 (Kroemer et al., 2007). The 
release of Cyt c from the mitochondria is partly regulated by B-cell lymphoma protein 2 
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(Bcl-2) family members, with anti-apoptotic (e.g., Bcl-2, Bcl-2-related protein, long 
isoform (Bcl-XL)) and pro-apoptotic (e.g., Bcl-2-associated X protein (Bax), Bcl-2-
antagonist/killer 1 (Bak), BH3-interacting domain death agonist (Bid)) activity (Reed, 
1997).  
Each pathway culminates in the activation of a proteolytic cascade involving the sequential 
breakdown of procaspases 3, 6, and 7, and hence their activation, by the corresponding 
initiator caspases. This execution phase leads to the cleavage of downstream cellular 
substrates that in part explain the biochemical and morphological changes during 
apoptosis.  
Alternatively, a third less well-known apoptotic pathway can occur, in which it is believed 
that caspase 12 is activated by the adapter protein TNF receptor-associated factor 2 
(TRAF2) as a result of an injured endoplasmic reticulum (O'Brien and Kirby, 2008). In 
addition, DNA damage can lead to apoptotic death through a p53-dependent pathway. The 
pro-apoptotic proteins Bax, phorbol-12-myristate-13-acetate-induced protein 1 (Noxa), and 
Bcl-2-binding component 3 (Puma) were described as transcriptional targets of p53. 
Alternatively, p53 can also activate death receptors and repress anti-apoptotic proteins 
(Amaral et al., 2010). 
Some of the described constituents of the apoptotic cascades have been pivotal for the 
design of new therapies. Anti-apoptotic members of these cascades are promising targets 
for new therapeutic agents, as ABT-737, a small molecule capable of inhibiting the activity 
of Bcl-XL through binding to its BH3 groove (Stauffer, 2007), and Oblimersen, an 
antisense oligonucleotide that inhibits the expression of Bcl-2 by blocking the translation 
of its mRNA (Moreira et al., 2006). Mapatumumab, a fully human agonistic monoclonal 
antibody, is another therapeutic alternative that binds and activates TRAIL-R1 (for TRAIL 
receptor 1) to induce apoptosis (Carlo-Stella et al., 2007). The induction of p53-dependent 
apoptosis can also be achieved with PRIMA-1 (for p53 reactivation and induction of 
massive apoptosis) and MIRA-1 (for mutant p53 reactivation and induction of rapid 
apoptosis), two compounds that reactivate the function of mutant p53 (Selivanova and 
Wiman, 2007), and with Nutlin-3 that binds to Mdm2 (human homologue of murine 
double minute 2, a negative regulator of p53) and inhibits the binding and ubiquitination of 
p53 (Vassilev, 2007). 
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1.2. Osteosarcoma 
1.2.1. Bone physiology 
Throughout life, bone tissue undergoes different processes. Longitudinal and radial growth 
of bones occurs mainly during childhood and adolescence, a rapid growth phase in an 
individual’s life. The process of bone modeling (change of the general bone shape 
influenced by physiological or mechanical forces) and bone remodeling (bone renewal to 
maintain mineral homeostasis and bone strength) are also important for safeguarding the 
health and performance of skeleton (Clarke, 2008). In one way or another, these critical 
processes are dependent on the action of two cellular types: osteoclasts and osteoblasts.   
Osteoclasts are cells capable of resorbing bone, which is essential for the removal of old, 
microdamaged bone tissue. These cells bind to bone matrix and secrete H+ ions and 
acidified vesicles containing MMPs, cathepsin K, and other enzymes (Teitelbaum et al., 
1995). The resorption area is limited by osteoclasts through a rearrangement of its 
cytoskeleton that forms a sealing zone wherein the degradation of bone tissue occurs 
(Vaananen et al., 2000).   
In contrast, osteoblasts are responsible for formation of new bone matrix on appropriate 
surfaces. Osteoblasts are generated from osteoprogenitor cells that descend from 
mesenchymal stem cells, and amongst osteoblasts’ functions one can count: synthesis of 
bone matrix components, such as collagen-related proteins; regulation of the 
mineralization process of bone matrix via release of vesicles that concentrate calcium and 
phosphate; and destruction of mineralization inhibitors, such as pyrophosphate or 
proteoglycans (Anderson, 2003). After bone formation, 50-70% of osteoblasts undergo 
apoptosis (Clarke, 2008). 
Bone remodeling is particularly highly dependent on the coupled action of osteoclasts and 
osteoblasts that sequentially remove old bone and replace it with newly synthesized and 
mineralized bone matrix. Thus, any imbalance in the osteoblast physiology may cause 
severe damages in the bone structure. 
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1.2.2. Osteosarcoma: epidemiology, clinical aspects, diagnostic methods, histologic 
features, and etiology 
Osteosarcoma (OS) or osteogenic sarcoma is a primary malignant bone tumor 
characterized by the formation of immature bone or osteoid (the unmineralized, organic 
component of bone matrix) by tumor cells.  
This tumor is the most frequent primary bone sarcoma, representing around 20% of all 
bone tumors, and the most common primary malignant bone tumor in children and 
adolescents (Marina et al., 2004; Tang et al., 2008). Nevertheless, OS is considered a rare 
disease, accounting for only 0.2% of all malignant tumors (Greenlee et al., 2001). OS has a 
bimodal age distribution, with a first and larger peak incidence during the second decade of 
life (the adolescent growth spurt) and a minor second peak in elderly adults (Marina et al., 
2004). Children and adolescents represent approximately 75% of OS patients (Picci, 2007) 
and boys are more frequently affected than girls (Marina et al., 2004). A slightly higher 
incidence of OS in African-American children than in Caucasian children is also reported 
(Marina et al., 2004). In 80-90% of cases, OS occurs in long tubular bones and is usually 
originated in the metaphysis. Children, adolescents, and young adults affected with this 
malignant disease normally present high-grade tumors in long bones of the extremities 
(rapid bone growth areas), including femur, tibia, and humerus (Marina et al., 2004; Tang 
et al., 2008; Gorlick and Khanna, 2010). In the second OS peak incidence, corresponding 
to individuals over the age 60, low-grade tumors are typically found in axial sites (Gorlick 
and Khanna, 2010). These differences may suggest different underlying mechanisms for 
the development of OS in younger and older patients. 
The most common and early symptom of OS (2-4 months before diagnosis) is pain, caused 
either by the stretching of the periosteum or bone deterioration due to stress fractures, and 
generally arises after vigorous physical exercise or trauma (Marina et al., 2004; Ta et al., 
2009). Some patients complain about swelling, related to soft tissue extension, and rare 
systemic symptoms as weight loss, pallor, fever, and anorexia can also be reported (Picci, 
2007). In 80% of cases, conventional OS is localized in one bone site, presenting 
metastases in about 20% of patients (Ta et al., 2009). Still, a great percentage of patients 
with localized OS (80%) develop metastatic disease after surgical resection, which means 
that almost all OS patients are affected by metastatic disease (Marina et al., 2004). The 
most frequent metastatic site is the lung, with secondary tumors occurring in this organ in 
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approximately 90% of patients with metastatic OS (Longhi et al., 2003; Gorlick and 
Khanna, 2010). Besides lung, bone metastases are also common, generally appearing after 
pulmonary metastases are already established (Ta et al., 2009). However, the occurrence of 
multiple bone metastases may actually reflect multifocal primary tumors (Marina et al., 
2004). “Skip metastases” (outside the reactive zone, but within the same bone or across the 
neighboring joint) and lymph node metastases are rare (Ta et al., 2009) and metastatic 
disease at OS recurrence can affect the central nervous system (Marina et al., 1993), as 
well. Death in OS patients is usually caused by progressive pulmonary metastasis that 
leads to respiratory failure (Marina et al., 2004). 
The initial imaging diagnostic modality for OS is commonly radiography, showing 
sclerotic, lytic or mixed lesions in the affected bone with periosteal elevation and often 
production of soft tissue swelling (Picci, 2007). Other important diagnostic methods 
include computed tomography and magnetic resonance imaging, which are useful to 
predict the tumor extension and determine surgical resection (Panicek et al., 1997). 
Elevated levels of alkaline phosphatase and lactate dehydrogenase have been reported to 
have prognostic significance (Marina et al., 2004; Picci, 2007). Biopsy of the affected area 
for confirmation is a mandatory step in diagnosis. 
Conventional OS consists of primary intramedullary high-grade sarcoma and presents a 
wide spectrum of histologic appearances that share common characteristics: proliferation 
of malignant mesenchymal stem cells and production of bone and/or osteoid (Marina et al., 
2004). Histologically, the World Health Organization classifies conventional OS in three 
major subtypes - osteoblastic, chondroblastic, and fibroblastic - that reflect the 
predominant type of matrix in the tumor, as well as the mesenchymal origin of the 
malignant cells and their ability to differentiate into various cell types (Raymond et al., 
2002). Osteoblastic OS is found in 70% of conventional OS cases (Tang et al., 2008) and 
is characterized by the production of osteoid or bone as the main type of matrix and the 
presence of malignant plasmacytoid to epithelioid osteoblasts (Marina et al., 2004). 
Chondroblastic and fibroblastic OS tumors account for 10% of conventional OS, each 
(Tang et al., 2008). The first subtype shows mostly chondroid matrix with malignant cells 
within the lacunae, while the second subtype is composed of malignant spindle cells with 
scarce osteoid (Marina et al., 2004). In addition to the conventional OS subtypes, 
anaplastic, telangiectatic, giant cell-rich, and small cell OS are recognized as rare OS 
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subtypes (Tang et al., 2008). Despite the variety found between patient samples and even 
within a single tumor, the clinical behavior of OS doesn’t seem to be affected by this 
divergence.  
The current understanding of OS etiology is still limited. Because the major peak incidence 
coincides with the adolescent growth spurt, it is believed that the occurrence of OS is 
correlated with rapid bone growth. This is supported by the fact that girls have an OS peak 
incidence a little earlier than boys, corresponding to the earlier age of growth spurt 
(Rytting et al., 2000). Exposure to radiation is the only well-established environmental risk 
factor already associated with OS (Weatherby et al., 1981; Mark et al., 1994), but the long 
period between radiation exposure and tumor appearance (10 to 20 years) suggests that this 
is not relevant for the development of most conventional OS tumors. Yet, radiation can be 
responsible for the appearance of rare OS cases in adults and the development of secondary 
OS in individuals that received radiation therapy for treatment of certain primary tumors 
(Tang et al., 2008). Orthopedic implant-related OS has also been reported in a few patients 
(Keel et al., 2001). Furthermore, several human genetic disorders and familial cancer 
syndromes are linked with higher incidence of OS: Li-Fraumeni syndrome, an autosomal 
dominant disorder characterized by a germline mutation of TP53, which encodes p53; 
Rothmund-Thomson, RAPADILINO, and Bloom syndromes, autosomal recessive 
disorders associated with mutations in RECQL4 (in the case of the first two syndromes) 
and BLM (in the case of Bloom syndrome), genes encoding RecQ DNA helicases; 
hereditary retinoblastoma, caused by a mutation in the Rb tumor suppressor gene; among 
others (Calvert et al., 2012). OS tumors observed in older age individuals can also relate to 
Paget's disease (Picci, 2007). 
1.2.3. Pathogenesis of osteosarcoma 
The underlying molecular mechanisms of OS pathogenesis are characterized by a vastly 
heterogeneous array of genomic abnormalities, which hampers the identification of 
consensus changes in the development of this malignant tumor.  
High levels of genomic instability, particularly chromosomal instability (CIN, elevated rate 
of gain or loss of entire chromosomes or sections of chromosomes), are often found in OS 
tumors (Selvarajah et al., 2006). Numerical CIN (caused by mitotic errors, segmental 
amplifications/deletions) usually leads to gene copy number alterations, whereas structural 
CIN (resultant from failure in DNA damage response mechanisms or replication errors) 
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promotes additional genomic rearrangements and chromosomal breakages. Such variety of 
outcomes in CIN results in complex and diverse aberrations among OS patients (Martin et 
al., 2012). Among the most commonly observed numerical abnormalities in OS, one can 
count gain of chromosome 1, loss of chromosomes 9, 10, 13, and/or 17, and 
partial/complete loss of the long arm of chromosome 6, whilst structural abnormalities 
include rearrangements of chromosomes 11, 19, and 20 (Marina et al., 2004). CIN-
dependent or -independent genetic alterations found in conventional OS consist of 
amplifications, deletions, mutations, or loss of heterozygosity affecting diverse tumor 
suppressors (e.g., RecQ4, p16Ink4a, p15Ink4b) and oncogenes (e.g., Cdk4, Mdm2) (Martin et 
al., 2012). Variation in the DNA methylation profile of genes encoding these same proteins 
is described in OS tumors, as well (Sadikovic et al., 2008a).  
Nevertheless, within this lack of consistency reported in genetic alterations of different OS 
tumors, the importance of the tumor suppressors p53 and Rb in OS pathogenesis was 
underlined by several studies. Alterations of TP53 by point mutations are present in 30% 
of OS tumors (Papachristou and Papavassiliou, 2007), while deletion or loss of 
heterozygosity has a frequency of approximately 40% (Martin et al., 2012). Functional 
inactivation of p53 at the post-translational level cannot be forgotten, since the oncoprotein 
Mdm2, a p53 inhibitor that promotes its degradation and downregulation of its 
transcription, is frequently amplified in OS metastases and at OS recurrences (Miller et al., 
1996). RB1, the gene encoding Rb, presents mutations and loss of heterozygosity 
associated with inactivation of Rb in 50% of OS tumors (Wadayama et al., 1994). 
Together with the amplification of Cdk4 gene found in 10% of OS cases (Martin et al., 
2012), Rb inactivation leads to an uncontrolled cell cycle through G1/S progression. 
Additionally, inactivation of p53 and Rb causes CIN in vivo (van Harn et al., 2010). The 
association of p53 and Rb with OS is further supported by the high risk of OS in 
individuals carrying a germline mutation of TP53 or RB1 (Calvert et al., 2012). 
As for the potential cancer cell responsible for OS development, our understanding is 
rather restricted. OS arises from mesenchymal cells that have or acquire the capacity to 
produce osteoid (Gorlick et al., 2003). OS tumors exhibit osteoblast-like features, but the 
presence of distinct histologic forms of OS and the broad range of differentiation status of 
OS cells (highly differentiated, poorly differentiated, undifferentiated) suggest that the cell 
of origin is preosteoblast and retains the potential for pluripotent differentiation (Gorlick et 
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al., 2003; Haydon et al., 2007; Gorlick and Khanna, 2010). Actually, emerging data 
suggest that OS should be regarded as a differentiation disease caused by genetic and 
epigenetic alterations that disrupt differentiation of mesenchymal stem cells (Tang et al., 
2008). Several signaling pathways, such as wingless-type (Wnt), bone morphogenic 
protein (BMP), and Hedgehog (Hh), play an important role in regulating osteogenic 
differentiation (Yuasa et al., 2002; Zhou et al., 2008). Transcription factors are also key 
regulators of this process. Among them, runt-related transcription factor 2 (Runx2) is a 
central player in osteogenic lineage commitment and terminal differentiation, and its 
transcription regulation and activity are complexly affected by numerous signaling 
pathways (including the ones described above), interaction with Rb, and epigenetic 
modifiers (Lian et al., 2004; Tang et al., 2008; Martin et al., 2011). The disruption of 
Runx2 signaling by these interactors may interrupt osteoblast differentiation and RUNX2 
overexpression resulting from gain and amplification of chromosome 6p12-p21, which 
encompasses the RUNX2 gene, is also probably involved in this pathogenesis (Won et al., 
2009; Martin et al., 2011). 
1.2.4. Conventional treatment approaches in osteosarcoma 
Surgical resection of localized OS tumors is crucial for the treatment of this disease. 
Currently, the surgical strategies to deal with OS include amputation, limb salvage 
(removal of tumor without amputation, with subsequent replacement of bones and joints 
with allografts or prosthetic devices), and rotationplasty, being limb salvage the choice for 
80-90% of patients (Picci, 2007). However, surgical treatment alone frequently fails in the 
eradication of OS because high-grade OS patients usually present micro-metastases 
(Marina et al., 2004). When surgery is not practicable, radiotherapy can be used, but 
presents limited effects (Picci, 2007). During the last three decades, the development of 
chemotherapeutic agents, as well as the efficient combination of chemotherapy regimens, 
improved the outcome for patients with OS. In fact, before the use of effective 
chemotherapy, surgical resection and/or radiotherapy only allowed 2-year overall survival 
rates of 15-20% (Gorlick et al., 2003; Marina et al., 2004). Nowadays, multimodal 
treatment programs are frequent, in which chemotherapy is not only applied after surgery, 
but also as a pre-surgery tool (neoadjuvant chemotherapy) (Gorlick et al., 2003). The most 
common chemotherapeutic agents used in OS treatment are Doxorubicin, Cisplatin, 
Ifosfamide, and Methotrexate, generally used in combination, and the mechanisms of 
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action of these drugs are described in Table 1. Other drugs, such as taxanes, may be used to 
sensitize cancer cells to conventional chemotherapeutic agents.  
When metastatic OS occurring in the lung is diagnosed, the nodules should be resected and 
pre- and post-operative chemotherapeutic treatment should be the same as that for patients 
with localized disease (Picci, 2007). In the case of metastatic OS located in other sites, the 
probability of tumor eradication is less than 5% (Bacci et al., 2003). Unfortunately, 
treatment failure is rather common in metastatic patients and recurrence of OS located in 
the lung occurs in 90% of them (Gorlick et al., 2003; Picci, 2007).  
Although the integration of chemotherapeutic agents in OS treatment programs has 
contributed to the achievement of better overall survival rates, recurrence of OS is still a 
major problem (Chou and Gorlick, 2006). The failure of current treatments suggests 
acquired resistance to chemotherapy and/or ability of metastatic cells to develop a 
protective microenvironment in the lung (Gorlick et al., 2003).  
 
Table 1. Mechanisms of action of conventional chemotherapeutic agents used in osteosarcoma 
treatment. Adapted from Ta et al. (2009). 
Agent Mechanism of action 
Doxorubicin Intercalates at point of local uncoiling of the DNA double helix and 
inhibits the synthesis of DNA and RNA 
Cisplatin Binds directly to tumor DNA and inhibits the synthesis of DNA through 
the formation of DNA cross-links 
Ifosfamide Causes crosslinking of DNA strands, inhibiting the synthesis of DNA 
and protein 
Methotrexate Inhibits the synthesis of purine and thymidylic acid by binding 
dihydrofolate reductase 
 
1.2.5. MG-63: an in vitro model for osteosarcoma 
The past few decades have been prolific in the development of cell isolation and culturing 
techniques, conducting to the emergence of multiple cell culture models. The use of cell 
lines allows the study of general cell biology, biocompatibility testing, drug discovery, 
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among others. In particular, cancer cell lines have been a useful instrument towards a better 
comprehension of this malignancy, and the subsequent identification of promising 
therapeutic agents and novel targets for specific therapies (Masters 2002; Sharma et al., 
2010). In general, OS cell lines derived from patient samples retain many markers of the 
osteoblast phenotype (Pautke et al., 2004), but their altered molecular background and 
their high proliferative rates explain the selection of these cell lines as in vitro OS models. 
The human OS MG-63 cell line is derived from a 14 years old Caucasian male and is 
deposited in the American Type Culture Collection (ATCC) center. In culture, these cells 
develop as an adherent monolayer, present a fibroblast-like morphology, and require 48 h 
for one population doubling (Mohseny et al., 2011). MG-63 cells size is approximately 1/6 
of the size of normal osteoblasts in culture and, contrarily to normal osteoblasts, MG-63 
cells do not vary their cell size dependent on cell density and do not show branching cell 
processes (Pautke et al., 2004).  
A molecular characterization with immunohistochemical and genetic data from MG-63 
demonstrated that these cells present disturbances that affect important signaling pathways. 
A homozygous deletion of CDKN2A, the gene coding for cyclin-dependent kinase inhibitor 
2A (also known as p16Ink4a), was found in these cells (Ottaviano et al., 2010). The 
complete deletion of CDKN2A may have serious effects on carcinogenesis, since p16Ink4a is 
no longer available to perform G1 cell cycle control through the inhibition of Cdk4. 
Moreover, MG-63 cells presented a wild-type TP53 and a normal chromosomal band 
17p13.1 (harboring the TP53 gene); however, levels of TP53 transcripts were found to be 
extremely low and p53 protein was not detectable by immunohistochemical staining 
(Ottaviano et al., 2010). The downregulation of p53 can be explained by post-
transcriptional regulation mechanisms of this protein (Vogelstein et al., 2000), but 
rearrangements of TP53 can also lead to the absence of TP53 transcripts in the TP53 wild-
type cell line MG-63 (Chandar et al., 1992). The lack of p53 may lead to uncontrolled 
proliferation of these OS cells, due to its crucial role in cell cycle and apoptosis, as well as 
in other relevant pathways. In addition, the important role of Runx2 is not limited to 
osteoblast lineage determination and differentiation, but a cell cycle-dependent expression 
of RUNX2 is required for the regulation of cell cycle progression at G1 in osteoblasts 
(Galindo et al., 2005). In MG-63 cells, Runx2 protein levels are constitutively expressed 
throughout the cell cycle (Lucero et al., 2012), suggesting the involvement of this protein 
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in the disrupted proliferative mechanism of this OS model. Furthermore, Sadikovic and 
colleagues reported that MG-63 present genomic imbalance, different DNA methylation 
profiles, and changes in gene expression when compared to normal osteoblasts, 
particularly showing hypomethylation and gain of OS-related genes accompanied by 
overexpression of these genes (Sadikovic et al., 2008b). 
Overall, the genetic scenario commonly found in OS patients and shared by MG-63 cells 
makes this cell line a representative in vitro model of OS. 
 
1.3. Sulforaphane 
1.3.1. Cruciferous vegetables, glucosinolates, and isothiocyanates  
Research on the action of bioactive constituents of plants has shown, during the last 
decades, their anti-carcinogenic properties and epidemiologic studies confirm that 
consumption of fruits and vegetables, particularly cruciferous vegetables, may decrease the 
frequency of certain cancer types (Beliveau and Gingras, 2007; Hayes et al., 2008). 
Cruciferous vegetables belong to the Brassicaceae family (formerly known as Cruciferae), 
and include economically important plants, as broccoli, cabbage, cauliflower, kale, 
bokchoy, Brussels sprouts, radish, and mustards. Among the phytochemicals that can be 
found at high concentrations in cruciferous vegetables is the group of glucosinolates 
(GLSs). This well-characterized group is responsible for the bitter or hot taste intensively 
present in mustard, radish, and horseradish (Hayes et al., 2008). GLSs are β-thioglucoside-
N-hydroxysulfates that when enzymatically hydrolyzed by the action of myrosinase (β-
thioglucoside glucohydrolase) originate different compounds (Fimognari and Hrelia, 
2007), as illustrated in Figure 4. One of the possible products of GLSs hydrolysis is a 
group of bioactive sulphur-containing compounds, named isothiocyanates (ITCs). GLSs 
and myrosinase are stored in separate cell compartments and their release is triggered by 
cell damages, such as microbial attack, insect predation, and food processing (e.g., 
chewing, cutting, boiling) (Fimognari and Hrelia, 2007). However, recent data show that 
GLSs hydrolysis can also be mediated by the microflora of the mammalian gastrointestinal 
tract (Lai et al., 2010). This means that besides the GLSs conversion occurring before the 
digestive process, further formation of ITCs may take place by myrosinase of the 
gastrointestinal tract microflora. 
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Figure 4. Bioconversion pathway of glucosinolates. The hydrolysis of GLSs catalyzed by myrosinase 
results in glucose release and formation of an instable intermediate compound (R-C(-SH)=N-O-SO3-), which, 
dependent on the reaction conditions, can originate ITCs, nitriles, or oxazolidine-2-thiones, among others. 
Extracted from Fimognari and Hrelia (2007). 
 
 
1.3.2. Sulforaphane and cancer   
Considerable research interest has been given in the past years to one particular ITC 
compound – sulforaphane (SFN, 1-isothiocyanato-4-(methylsulfinyl)-butane) – due to the 
variety of exerted anti-cancer effects (Clarke et al., 2008). SFN is the hydrolysis product of 
the GLS precursor glucoraphanin (4-(methylsulfinyl)butyl glucosinolate) (Figure 5) and is 
found at particular high levels in broccoli and broccoli sprouts (Fahey et al., 1997). 
The great interest in SFN is related to its ability to simultaneously modulate multiple 
cellular targets involved in different stages of cancer development that include: DNA 
protection by modulation of carcinogen-metabolizing enzymes; inhibition of cell 
proliferation and induction of apoptosis; and inhibition of tumor angiogenesis and 
metastases formation. Therefore, SFN is able to prevent cancer initiation, as well as act on 
cancer cells as a therapeutic agent (Fimognari and Hrelia, 2007). 
The basis for anti-cancer SFN effects rely on the highly electrophilic central carbon in the -
N=C=S group. This structural feature enables SFN to bind to proteins and modify their 
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Figure 5. Enzymatic conversion of glucoraphanin to sulforaphane and the respective chemical 
structures. Extracted from Cwik et al. (2010). 
 
 
function, controlling various physiological processes, including the ones directly involved 
in the cancer phenotype (Fimognari et al., 2012). Another interesting property of SFN that 
makes this ITC a promising candidate in cancer therapy is the lack of systemic toxicity. A 
phase I clinical study evaluated broccoli sprouts preparations of GLSs (25 to 100 µM) and 
ITCs (25 µM), mainly containing SFN, and no significant cytotoxicity was observed with 
any of the preparations (Shapiro et al., 2006). Moreover, the in vitro and in vivo effects of 
SFN lead to the acceptance of this ITC as a promising anti-cancer agent and several 
ongoing phase I and phase II clinical trials are evaluating SFN potential in the treatment of 
breast and prostate cancers (USNIH, 2012).  
In the next sections, some of the pathways affected by SFN activity in the 
chemopreventive and chemotherapeutic perspective will be described.   
1.3.3. Chemopreventive and chemotherapeutic pathways targeted by sulforaphane 
1.3.3.1. Modulation of Phase I and Phase II enzymes 
The first step of cancer prevention is the blockage of carcinogens that may cause DNA 
damage and, consequently, cancer initiation. When these compounds enter the body, they 
are subjected to metabolic reactions by the cytochrome P450 enzymes (CYPs) or Phase I 
enzymes, causing gain of hydrophilic properties. At the same time, carcinogens are 
converted to highly reactive intermediates that can bind and damage macromolecules, such 
as DNA, RNA, and proteins (Juge et al., 2007). Chemopreventive mechanisms of action of 
SFN involve the detoxification of carcinogens by inhibition of Phase I enzymes through 
regulation of the expression and function of different CYPs (Maheo et al., 1997; Langouet 
et al., 2000).  
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On the other hand, Phase II enzymes also play an important role in carcinogenics 
detoxification, contributing to their elimination and hence protecting cells against them 
(Higdon et al., 2007). The effect of SFN at this level is based on the induction of Phase II 
enzymes and a large number of proteins involved in this cellular defense mechanism were 
found to be significantly induced by this ITC: epoxide hydrolase (Thimmulappa et al., 
2002), glutathione reductase (Wu and Juurlink, 2001; Hu et al., 2006), glutathione 
peroxidase (Cornblatt et al., 2007), glutathione S-transferase (Zhang et al., 1992), 
thioredoxin and thioredoxin reductase (Hu et al., 2006), among others. 
The induction of Phase II enzymes by SFN is in part accomplished by the regulation of 
their expression. SFN reacts with thiol groups on Kelch-like ECH-associated protein 1 
(Keap1), which promotes nuclear factor erythroid 2-related factor 2 (Nrf2) dissociation 
from Keap1, allowing the activation of antioxidant response element (ARE)-driven gene 
expression of Phase II enzymes (Zhang et al., 1992). 
1.3.3.2. Induction of cell cycle arrest 
The anti-proliferative effect of SFN on different cancer cells is the result of cell cycle 
arrest at G0/G1, G2/M, or S phase through diverse mechanisms. In this respect, SFN can 
directly regulate the expression of cyclins and CDKs that control progression through 
specific cell cycle phases (Singh et al., 2004b; Cho et al., 2005; Kim et al., 2011). In 
addition to the control of the main drivers of cell cycle progression, SFN can modulate the 
expression of other proteins that influence the activity of the former. Levels of Cdc25 
phosphatases were found to be downregulated in prostate cells upon SFN exposure (Singh 
et al., 2004b) and members of the Cip/Kip family (e.g., p21Cip1, p27Kip1) that act as CKI 
usually suffer SFN-induced upregulation in cancer cells (Parnaud et al., 2004; Shan et al., 
2006; Shen et al., 2006). The disruption of microtubules by inhibition of tubulin 
polymerization was also reported by Jackson and Singletary and associated with SFN-
induced cell cycle arrest (Jackson and Singletary, 2004a). Microtubules formation is 
essential for a correct mitotic process and the inhibition of mitotic spindle formation during 
this cell cycle phase prevents a normal outcome in cell division.   
1.3.3.3. Induction of apoptosis  
Resistance to apoptosis in cancer cells is a major problem encountered in cancer therapy. 
SFN is a well-known apoptotic inducer and the mechanisms underlying this effect seem to 
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be dependent on the cancer cell type. In non-tumorigenic and tumorigenic malignant 
glioblastoma cell lines (T98G and U-87MG, respectively) SFN induced apoptosis through 
different ways; both caspase-dependent and caspase-independent pathways are suggested 
to be involved in the SFN-induced apoptosis in these cells (Karmakar et al., 2006). 
Different upstream regulators of apoptosis, as p53 (Fimognari et al., 2002; Fimognari et 
al., 2004), second mitochondria-derived activator of caspase/direct IAP-binding protein 
with low pI (Smac/DIABLO) (Karmakar et al., 2006), and Bax (Singh et al., 2004a), are 
proposed to mediate this programmed cell death after SFN exposure.  
Interestingly, SFN ability to surpass Doxorubicin resistance to the induction of apoptosis in 
cells carrying different p53 mutations was suggested by Fimognari and collaborators 
(2007); the induction of apoptosis in these cells was achieved by mediation of selective 
activation of certain executioner caspases after exposure to a combination of SFN and 
Doxorubicin (Fimognari et al., 2007). 
In recent years, SFN was identified as a histone deacetylase (HDAC) inhibitor and its role 
as a modulator of epigenetic processes that lead to apoptosis is described in the literature, 
as well. SFN was reported to induce apoptosis via promotion of the expression of genes 
encoding pro-apoptotic proteins, as p21Cip1 (Myzak et al., 2006b). In this in vitro study, 
histone-induced p21Cip1 gene repression was reverted by the increase of acetylated histones 
H3 and H4. In vivo experiments support this mechanism of apoptosis induction by SFN, as 
mice treated with SFN were reported to present significant inhibition of HDAC activity in 
the colonic mucosa with concomitant increase in acetylated histones H3 and H4 (Myzak et 
al., 2006a). 
1.3.3.4. Inhibition of angiogenesis and metastasis 
An important event that enables tumor progression – angiogenesis – can also be modulated 
by SFN. Using human umbilical vein endothelial cells (HUVEC cell line) as an in vitro 
model for angiogenesis, Asakage and colleagues demonstrated that SFN inhibited the 
proliferation of these cells in a dose-dependent manner, as well as tube formation on 
matrigel; according to the authors the antiproliferative effect was dependent on cell 
apoptosis (Asakage et al., 2006). Moreover, an in vitro study performed with HMEC-1, an 
immortalized human microvascular endothelial cell line, showed that SFN interferes with 
angiogenic signaling pathways, inhibiting mRNA expression of two angiogenesis-
associated transcription factors (HIF-1α and Myc proto-oncogene protein (c-Myc)) in a 
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concentration range of 0.8 to 25 µM and transcription of VEGF receptor KDR/flk-1 (for 
kinase insert domain receptor/fetal liver kinase 1), and affects basement membrane 
integrity (Bertl et al., 2006). 
Other crucial step of carcinogenesis is the formation of metastases. Evidences show that 
the use of SFN in combination with TRAIL is more effective in inhibiting metastatic 
markers (Shankar et al., 2008). SFN also reduced the invasive potential of B16F-10 
melanoma cells through inhibition of activation of MMP-2 and MMP-9, accompanied by 
95.5% inhibition of lung tumor nodule formation (Thejass and Kuttan, 2006).    
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II. OBJECTIVES 
 
 
Despite the remarkable advances in OS therapy over the past few decades, OS patients still 
present high resistance rates to the current treatment approaches (Chou and Gorlick, 2006), 
demanding urgent action on the discovery/development of new therapeutic agents. The 
cytotoxic effect of SFN has been described for multiple cancers, as well as other human 
diseases. The ability of modulate apoptosis and cell cycle progression are desired 
properties to be found in chemotherapeutic agents and SFN has proven to exert them at 
different stages of the carcinogenic process (Fimognari and Hrelia, 2007). However, 
literature lacks information about the effects of SFN in OS and the mechanisms that lead to 
these effects have not been fully understood yet.  
Therefore, the main objectives of the present dissertation were to evaluate the potential of 
SFN as a cytostatic and pro-apoptotic agent for OS cells and to provide insight about the 
mechanisms of action of SFN underlying the modulation of cell cycle progression and 
apoptotic pathways. In this context, the work presented in this dissertation purposes to:  
 
1) assess the viability status of cells; 
2) evaluate cell distribution throughout cell cycle; 
3) elucidate the type of cell death behind cytotoxicity; 
4) measure the activity level of different caspases in order to determine the activated 
apoptotic pathway(s); 
5) and quantify the expression of genes encoding proteins involved in cell cycle 
regulation, after exposure of an in vitro OS model to different concentrations of SFN. 
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III. MATERIALS AND METHODS 
 
3.1. Materials and reagents 
α-Minimum Essential Medium (α-MEM), fetal bovine serum (FBS), fungizone, penicillin-
streptomycin, Trypsin-ethylenediaminetetraacetic acid (EDTA), 1X phosphate-buffered 
saline (PBS) pH 7.2, TRIzol reagent, and the kit DNase I - Amplification grade were 
purchased from Life Technologies (Carlsbad, CA, USA). D,L-sulforaphane (SFN), 
dimethyl sulfoxide (DMSO), 3-(4,5-dimethyl-thiazolyl-2)-2,5-diphenyl tetrazolium 
bromide (MTT), propidium iodide (PI), ribonuclease (RNase), bovine serum albumin 
(BSA), and Bradford reagent were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Ethanol and chloroform were obtained from Merck Millipore (Darmstadt, Germany). FITC 
Annexin V Apoptosis Detection Kit I was purchased from BD Biosciences (San Jose, CA, 
USA) and APOPCYTO Caspase-3 Colorimetric Assay Kit from MBL International 
Corporation (Woburn, MA, USA). Caspase-8 Colorimetric Activity Assay Kit and 
Caspase-9 Colorimetric Activity Assay Kit were purchased from Chemicon-Millipore 
(Temecula, CA, USA). RNeasy Mini Kit and Omniscript RT Kit were obtained from 
Qiagen (Hilden, Germany). Kanamycin positive control RNA and iQ SYBR Green 
Supermix were purchased from Promega (San Luis Obispo, CA, USA) and Bio-Rad 
(Hercules, CA, USA), respectively. 
3.2. Cell culture 
The human OS cell line MG-63 (CRL-1427, ATCC, Vanassas, VA, USA) was used as an 
in vitro OS model and was kindly provided by INEB (Instituto Nacional de Engenharia 
Biomédica, Universidade do Porto, Portugal). MG-63 cells were cultured in α-MEM 
supplemented with 10% FBS, 2.5 µg/mL fungizone, and penicillin-streptomycin (100 
U/mL-100 µg/mL). Cells were cultured in 75 cm2 culture flasks with 10 mL supplemented 
medium and maintained at 37 °C in a 5% CO2 humidified atmosphere. Cell cultures were 
routinely observed under an inverted microscope to verify their confluence, the 
morphology and viability of cells, and the absence of microorganism contaminations.  
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Subculture was performed every 3-4 days, when cultures reached approximately 70% 
confluence. After removal of the culture medium, cells were washed with 5 mL PBS and 
incubated with 3 mL Trypsin-EDTA (0.25% trypsin, 1 mM EDTA) for 5 min, to cleave 
proteins that enable cell adherence to the flask and cell-cell adhesion. After cell 
detachment from the culture flask, trypsin was inactivated by adding 6 mL supplemented 
medium to the culture. Cells were harvested, counted using a TC10 Automated Cell 
Counter (Bio-Rad, Hercules, CA, USA), and seeded (1x105 cells/mL) in a new culture 
flask with a final volume of 10 mL of supplemented medium. 
3.3. Sulforaphane preparation and cell exposure  
D,L-sulforaphane was dissolved in DMSO in order to prepare 10 mM SFN stock solutions, 
which were stored at -20 ºC. Before every treatment, SFN stock solutions were thawed and 
diluted in supplemented medium to a concentration of 100 µM SFN. This solution was 
transferred to a syringe (Terumo, Leuven, Belgium) and forced through a 0.2 µm syringe 
filter (VWR International, Radnor, PA, USA) with a cellulose acetate membrane to obtain 
a sterile SFN solution. The desired SFN concentrations (5, 10, and 20 µM) were then 
prepared by serial dilutions with supplemented medium from the sterile 100 µM SFN 
solution. 
For each experiment, cells were seeded and allowed to adhere for 24 h (37 ºC, 5% CO2). 
After this period, the medium was removed and replaced by fresh medium containing SFN 
at final concentrations of 5, 10, and 20 µM or fresh medium without SFN (0 µM SFN) in 
the case of control cells. SFN-treated cultures were exposed to <0.5% DMSO. The effect 
of SFN was measured after exposure periods of 24 and 48 h in the same temperature and 
controlled atmosphere conditions.  
3.4. Characterization of confluence and cell morphology 
Cells were visualized under an inverted microscope in order to characterize, in a qualitative 
manner, general aspects of cells that can reflect their functional status and viability. 
Confluence and cell morphology (e.g., shape, volume, attachment/detachment status) of 
SFN-treated cultures were described and compared with control cultures. 
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3.5. Cell viability 
The effect of SFN on cell viability was evaluated by the colorimetric MTT assay. This 
assay depends on the ability of mitochondrial enzymes to reduce MTT, a soluble, yellow 
tetrazolium salt, into an insoluble, purple formazan product. The formazan crystals can be 
dissolved in various organic solvents and measured spectrophotometrically. Because 
reduction of MTT can only occur in metabolically active cells, the amount of formazan 
produced is proportional to the number of viable cells. 
The MTT assay was performed according to Twentyman and Luscombe (1987) with slight 
modifications. Cells were seeded in 96-well plates at 1x105 cells/mL and 0.7x105 cells/mL 
for 24 and 48 h exposure periods, respectively, in a final volume of 100 µL supplemented 
medium/well. The initial number of cells to use was selected with the view to obtain 
control samples yielding an absorbance between 0.75 and 1.25. After each exposure 
period, 50 µL MTT solution (1 mg/mL PBS) were added to each well and cells were 
incubated for 4 h at 37 ºC, 5% CO2, in darkness. At this point, the medium and the MTT 
solution were aspirated from the wells using a syringe with a needle (Terumo, Leuven, 
Belgium) in order to avoid the disturbance and removal of the produced formazan crystals. 
Cells were incubated with DMSO (150 µL/well) for 2 h with gentle shaking, at room 
temperature and protected from light, to dissolve the formazan crystals. The absorbance of 
each well was measured at λ = 570 nm using a Synergy HT Multi-Mode Microplate 
Reader controlled via Gen5 Data Analysis Software (BioTek Instruments, Winooski, VT, 
USA). One hundred and fifty microliters DMSO/well were used as blank and the mean 
absorbance of blank replicates was subtracted from the total absorbance of each sample. 
Relative cell viability was calculated using the following equation: 
 
Relative viability (%) = (A570 of sample / mean A570 of control) x 100 
3.6. Cell cycle and clastogenicity analysis 
The measurement of the DNA content of single cells is one of the most universal 
applications of flow cytometry. Analyzing the content of DNA also provides information 
about the cell cycle, allowing one to determine the percentage of cells within a population 
that are undergoing G1/G0, S, and G2/M phases. This analysis relies on the use of dyes 
(e.g., PI) that bind specifically and stoichiometrically to nucleic acids and which 
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fluorescence is enhanced on binding. The cell cycle status of a population can then be 
reflected on a histogram plotting the number of cells vs. DNA content. 
For this experiment, cells (1.5x105 cells/mL) were seeded in 6-well plates, each well 
containing a final volume of 2 mL supplemented medium. At the end of each exposure 
period, control and treated cells were washed with 1 mL PBS/well, trypsinized using 360 
µL Trypsin-EDTA/well and 720 µL supplemented medium/well to inactivate the trypsin, 
and harvested. Subsequently, cell suspensions were centrifuged at 300 x g for 5 min, the 
supernatant was carefully removed and discarded, and the pellet was resuspended in 1 mL 
PBS. Another centrifugation was performed in the same conditions and cells were fixed 
with 1 mL 85% ethanol at 4 ºC, after discarding the supernatant. Samples were stored (-20 
ºC) until flow cytometric analysis.  
At the time of analysis, fixed cells were centrifuged (300 x g, 5 min), resuspended in 800 
µL PBS, and filtered through a 35 µm nylon mesh (to separate aggregated cells and 
remove large debris) into a 5 mL tube. Afterwards, 50 µL RNase (50 µg/mL) and 50 µL PI 
(50 µg/mL) were added to each sample followed by an incubation period of 20 min at 
room temperature, in darkness. This step ensures RNA elimination and DNA staining by 
RNase and PI, respectively. Finally, the relative fluorescence intensity of PI-stained nuclei 
was measured through a COULTER EPICS XL Flow Cytometer (Coulter Electronics, 
Hialeah, FL, USA) equipped with an air-cooled argon-ion laser turned at 15 mW and 
operating at 488 nm. The amplification was adjusted so that the peak corresponding to the 
diploid peak was positioned at channel 200. At least 5,000 events were analyzed for each 
sample. Acquisitions were made using SYSTEM II Software version 3.0 (Coulter 
Electronics, Hialeah, FL, USA). Doublets (clustered cells), nuclei with associated 
cytoplasm, partial nuclei, and other debris were excluded from the analysis by gating a 
region that encloses only single cells on the cytogram of the fluorescence light intensity 
pulse integral vs. the fluorescence light intensity pulse height. The cell cycle analysis was 
conducted based on the histogram outputs and percentages were estimated as number of 
nuclei in each cell cycle phase / total number of nuclei x 100. In order to assess the 
putative clastogenic effect of SFN on MG-63 cells, full peak coefficient of variation 
(FPCV) of G1/G0 nuclei was determined in each histogram as diagnostic for clastogenic 
damage, as recommended by Misra and Easton (1999). 
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3.7. Apoptosis assessment 
Apoptosis consists of multiple biochemical events that trigger characteristic morphological 
and functional changes in the cell, culminating in its death. Amongst all, the loss of plasma 
membrane asymmetry is one of the earliest morphologic alterations occurring during the 
apoptotic process, in which the membrane phospholipid PS is translocated from the inner 
to the outer leaflet of the plasma membrane. Annexin V, a 35-36 kDa calcium-dependent 
phospholipid-binding protein, shows high affinity for PS, binding to cells that present this 
phospholipid on the surface of the plasma membrane. When conjugating Annexin V with a 
fluorochrome, such as fluorescein isothiocyanate (FITC), this conjugate can be used as a 
sensitive probe for flow cytometric analysis of cells undergoing apoptosis. Also, since non-
viable cells and cells undergoing late stages of apoptosis lose plasma membrane integrity 
and are permeable to viability probes (e.g., PI), the simultaneous use of FITC Annexin V 
and PI allows to distinguish early and late apoptotic cells. Therefore, using FITC Annexin 
V and PI in conjunction in a flow cytometric analysis will enable the quantification of: 
viable cells (both FITC Annexin V and PI negative); cells in early apoptosis (FITC 
Annexin V positive and PI negative); cells in late apoptosis (both FITC Annexin V and PI 
positive); and necrotic cells (FITC Annexin V negative and PI positive).   
Apoptosis assessment was performed using the FITC Annexin V Apoptosis Detection Kit 
I. In this assay, 1x105 cells/well in 2 mL supplemented medium were seeded in 6-well 
plates. After SFN exposure, cells were washed with 1 mL PBS/well and trypsinized (360 
µL Trypsin-EDTA/well). After trypsin inactivation with 720 µL supplemented 
medium/well, cells were collected, briefly vortexed, and counted. Cell suspensions were 
centrifuged for 5 min at 4 ºC and 300 x g, the supernatant was discarded, and 1 mL cold 
PBS was added without resuspension of the pellet. This previous step was repeated 
entirely, but cells were then resuspended in 1X Annexin V Binding Buffer (1 volume of 
10X Annexin V Binding Buffer to 9 volumes of distilled H2O) at 1x106 cells/mL. One 
hundred microliters of each cell suspension were transferred to a 5 mL tube and 5 µL FITC 
Annexin V and 5 µL PI were added to each sample. After incubation (15 min, room 
temperature, in darkness), 400 µL 1X Annexin V Binding Buffer were added to each tube 
and samples were analyzed by flow cytometry within 1 h. The following controls were 
used to set up compensation and quadrants: unstained cells; cells stained with FITC 
Annexin V (no PI); and cells stained with PI (no FITC Annexin V). At least 10,000 events 
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were analyzed for each sample and percentages were estimated as number of cells in each 
quadrant / total number of cells x 100. 
3.8. Protein quantification 
The Bradford protein assay is a protein determination method based on the binding of 
Coomassie Brilliant Blue G-250 dye to proteins, which leads to the conversion of the 
protonated red cationic form in the unprotonated blue form of the dye (Bradford, 1976). 
The latter shows Amax = 595 nm, allowing the spectrophotometric quantification of protein-
dye complexes at this wavelength, and hence protein content determination. When needed, 
total protein in samples was quantified by the Bradford protein assay. Briefly, 5 µL of cell 
extract of unknown protein concentration were incubated with 250 µL Bradford reagent in 
a flat-bottom, clear polystyrene 96-well microplate for 10 min, protected from light and 
shaken. The buffer of each sample was used as blank. Absorbance of samples was read at λ 
= 595 nm in the previously described microplate reader. A BSA standard curve was 
generated by measuring the absorbance of samples with known concentrations of BSA (in 
the 0 to 1.4 mg/mL ultrapure H2O range) and protein concentration of the cell extracts was 
determined by comparison. Whenever needed, cell extracts were diluted in the respective 
buffers to fit in the BSA concentration range. 
3.9. Caspase activity assessment 
After activation by a variety of signals, caspases recognize and cleave a wide number of 
different substrates, leading to the activation of different apoptotic pathways. The detection 
of caspase activity is recognized as a standard method to measure apoptosis. Active 
caspases recognize 4-5 amino acid sequences in a substrate molecule. For caspases 3, 8, 
and 9 this sequence is DEVD, IETD, and LEHD, respectively. In the present work, the 
assessment of the activity of these three caspases relied on the use of a synthetic substrate 
consisting of a peptide, enclosing the specific sequence recognized by each caspase, 
labeled with the chromophore p-nitroanilide (pNA) at the C-terminal side. pNA is released 
from the labeled synthetic substrate on cleavage by active caspase. Because the amount of 
free pNA is proportional to the amount of caspase activity present in a sample, caspase 
activity can be determined by measuring spectrophotometrically the absorbance of free 
pNA at λ = 405nm.   
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3.9.1. Caspase 3 activity 
Caspase 3 activity was measured using the APOPCYTO Caspase-3 Colorimetric Assay Kit 
according to manufacturer’s protocol, with few alterations. For this assay, 2.5x106 cells 
were seeded in 150 mm cell culture dishes using 20 mL supplemented medium and 
subjected to control and SFN treatment (10 and 20 µM) conditions for 48 h. Ended this 
period, cells were washed with 10 mL PBS and trypsinized with 8 mL Trypsin-EDTA, 
which was inactivated with 16 mL supplemented medium. After determining the cell 
density, 1.5x106 cells were collected from each sample and centrifuged at 400 x g for 5 
min, at 4 ºC. The supernatant was discarded and cells were resuspended in 100 µL ice-cold 
Cell Lysis Buffer and incubated on ice for 10 min. Cell lysates were centrifuged at 10,000 
x g for 5 min at 4 ºC, to precipitate cellular debris, and the supernatant (cell extract) was 
transferred to new microtubes and placed on ice. Total protein concentration of the cell 
extracts was measured by the Bradford protein assay, as described above. Fifty microliters 
of 2X Reaction Buffer containing 10 mM dithiothreitol (DTT), 50 µL of cell extract, and 5 
µL 10 mM Caspase-3 Substrate (Substrate DEVD-pNA) were added to each well of a 
polystyrene 96-well microplate. To measure the blank absorbance, wells with 50 µL Cell 
Lysis Buffer instead of cell extract were prepared. Also, to verify that the signal detected 
by the kit was generated by protease activity, 1 µL 1 mM Inhibitor DEVD-FMK was 
added to wells already containing the cell extract and the reaction buffer, adding the 
Caspase-3 Substrate after 10 min. The microplate was then covered with a plate sealer and 
incubated at 37 ºC, protected from light, for 18 h. Absorbance in the wells was measured at 
λ = 405 nm in a microplate reader. For construction of a pNA standard curve, 100 µL pNA 
standards (0 to 500 µM pNA prepared by serial dilutions from a 100 mM pNA Standard in 
Cell Lysis Buffer) were added to empty wells and the absorbance was measured at λ = 405 
nm.       
3.9.2. Caspase 8 and caspase 9 activity 
The activity of caspase 8 and caspase 9 was measured using the Caspase-8 Colorimetric 
Activity Assay Kit and Caspase-9 Colorimetric Activity Assay Kit, respectively, following 
the manufacture’s instructions with slight modifications. For both assays, 150 mm cell 
culture dishes with 20 mL supplemented medium were used and cells were seeded at a 
concentration of 2.5x106 cells/dish. After 48 h of SFN exposure, treated (10 and 20 µM 
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SFN) and untreated cells (control) were washed (10 mL PBS), trypsinized (8 mL Trypsin-
EDTA and 16 mL supplemented medium for trypsin inactivation), and counted. From each 
sample, 1.5x106 cells were harvested and centrifuged at 1,500 rpm for 10 min, at 4 ºC. The 
pellet was resuspended in 100 µL chilled 1X Cell Lysis Buffer (1 volume of 5X Cell Lysis 
Buffer to 4 volumes of ultrapure H2O) and incubated on ice for 10 min, followed by 
another centrifugation at 10,000 x g for 5 min, at 4 ºC. The supernatant (cell extract) was 
transferred to new microtubes (placed on ice) and the total protein concentration of each 
cell extract was measured by the Bradford protein assay. An assay mixture containing 20 
µL 5X Assay Buffer, 50 µL of cell extract, 20 µL ultrapure H2O, and 10 µL Caspase-8 
Substrate (2.5 mg/mL Ac-IETD-pNA) or Caspase-9 Substrate (3 mg/mL Ac-LEHD-pNA) 
was prepared in wells from a 96-well microplate for each sample. Additional wells 
containing the same volumes of 5X Assay Buffer and cell extract, but with 15 µL ultrapure 
H2O, were pre-incubated with 5 µL Caspase-8 Inhibitor (100 µM Ac-IETD-CHO) or 
Caspase-9 Inhibitor (100 µM Ac-LEHD-CHO), for 10 min at room temperature, being the 
corresponding substrate added subsequently. In the case of blank samples, this mixture 
consisted of 20 µL 5X Assay Buffer, 70 µL ultrapure H2O, and 10 µL Caspase-8 Substrate 
or Caspase-9 Substrate. The microplate was sealed and incubated for 2 h at 37 ºC, in 
darkness. Wells’ absorbance was read at λ = 405 nm using a microplate reader. One 
hundred microliters pNA standards (0 to 500 µM) were added to empty wells, after 
diluting the provided 10 mM pNA Standard in 1X Assay Buffer (1 volume of 5X Assay 
Buffer to 4 volumes of ultrapure H2O), and the absorbance was measured at λ = 405 nm. A 
pNA standard curve was constructed for extrapolation of caspase activity in samples.   
3.9.3. Determination of caspase specific activity  
For all caspase activity assays, the specific activity of caspase was calculated as follows: 
the mean of the replicate blank readings was subtracted from the absorbance values of each 
sample; the corresponding free pNA concentration was determined using the pNA standard 
curve; caspase activity present in each sample was calculated using the equation: 
 
Caspase activity (CA) = (free pNA concentration (µM) x 0.1 mL) / incubation hour 
 
Finally, specific activity of caspase in each sample was estimated by the formula: 
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Specific Activity = CA / (total protein concentration (mg/mL) x 0.1 mL)  
3.10. Gene expression 
3.10.1. Primers 
For primer design, the consensus coding DNA sequence (CDS) of the genes of interest was 
acquired from the National Center for Biotechnology Information “Gene” database 
(http://www.ncbi.nlm.nih.gov/gene/) (when multiple CDSs were found for one gene, the 
largest overlap region from the different CDSs was obtained from the multiple sequence 
alignment tool Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/)). Specific 
primers were selected using Primer3 version 0.4.0. (http://frodo.wi.mit.edu/primer3/) 
(Rozen and Skaletsky, 2000). Primer pairs were tested for specificity using the University 
of California Santa Cruz In-Silico PCR database (http://genome.ucsc.edu/cgi-bin/hgPcr). 
Table 2 shows the oligonucleotide primer list for quantitative reverse transcription 
polymerase chain reaction (qRT-PCR) to analyze the expression of CHEK1, CHEK2, 
CDK1, CDK2, CDC25C, and CCNB1. Amplification of the housekeeping gene GAPDH 
was performed as an internal reference for relative quantification. The following external 
control primers (for kanamycin positive control) were used as control for GAPDH 
expression stability relative to total RNA amounts: Kan-F: 5’-
AGCATTACGCTGACTTGACG-3’; Kan-R: 5’-AGGTGGACCAGTTGGTGATT-3’.  
3.10.2. RNA extraction 
Cells were seeded (1x105 cells/well) in 6-well plates with 2 mL supplemented medium. 
After 48 h of SFN exposure (10 µM), medium from treated and untreated cultures was 
discarded and cells were washed twice with 1 mL PBS/well. Cell lysis was performed 
adding per well 333 µL TRIzol reagent. Cell lysate of replicates of the same condition 
were transferred to a 2 mL RNase-free tube and stored frozen (-80 ºC) until analysis. At the 
time of analysis, 200 µL chloroform were added to each tube, shaken on vortex for 10 s, 
and incubated at room temperature for 2 min. The TRIzol-chloroform mixtures were 
poured into previously centrifuged (1 min at maximum rpm) 2 mL Phase Lock Gel tubes 
(5 Prime, Hamburg, Germany) and went through a centrifugation at 12,000 x g for 15 min. 
The aqueous top phase (containing the RNA) was transferred to a 1.5 mL RNase-free tube 
(about 600 µL) and an identical volume of RNase-free 70% ethanol (in 
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Table 2. Specific oligonucleotide primers used in qRT-PCR for gene expression analysis. 
Target gene Product Forward primer (5’-3’) Reverse primer (5’-3’) 
CHEK1 Checkpoint kinase 1 (Chk1) CCCGCACAGGTCTTTCCTT CGTGTCATTCTTTTGACCAACC 
CHEK2 Checkpoint kinase 2 (Chk2) CACAGCTCTACCCCAGGTTC CACAACACAGCAGCACACAC 
CDK1 Cdk1 GGGTAGACACAAAACTACAGGTCAA GGAATCCTGCATAAGCACATC 
CDK2 Cyclin-dependent kinase 2 (Cdk2) ACCTCCCCTGGATGAAGATG AGATGGGGTACTGGCTTGGT 
CDC25C M-phase inducer phosphatase 3 (Cdc25C) CCTATGCATCATCAGGACCAC GGCTCATGTCCTTCACCAGA 
CCNB1 Cyclin B1 GCTGAAAATAAGGCGAAGATCAA ACCAATGTCCCCAAGAGCTG 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase ACACCCACTCCTCCACCTTT TACTCCTTGGAGGCCATGTG 
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diethylpyrocarbonate (DEPC)-treated H2O) was added to each tube to promote selective 
binding of RNA to the RNeasy membrane in the next step. The RNeasy Mini Kit was used 
from this point on with adaptations to its protocol. From each sample, 600 µL were 
transferred to an RNeasy Mini Spin Column placed in a 2 mL Collection Tube, centrifuged 
for 15 s at 10,000 rpm, and the flow-through was discarded. The same column and tube 
were reused to repeat the previous step with the remaining volume of sample. Seven 
hundred microliters Buffer RW1 were added to the column, followed by a centrifugation at 
10,000 rpm for 15 s and the discard of the flow-through. This step ensures the efficient 
removal of biomolecules, such as carbohydrates,proteins, fatty acids, etc., that are non-
specifically bound to the RNeasy membrane, allowing the binding of large RNA molecules 
(>200 bases) in the column.  Then, 500 µL Buffer RPE were added to the column and, 
after a centrifugation at 10,000 rpm for 15 s, the flow-through was discarded. This step was 
performed with the view to remove traces of salts. The previous step was entirely repeated, 
performing a centrifugation for 2 min to dry the RNeasy membrane, ensuring that no 
ethanol was carried over. The RNeasy Mini Spin Column was then carefully transferred 
from the Collection Tube to a 1.5 mL RNase-free tube, 40 µL RNase-Free Water were 
added directly to the RNeasy membrane, and samples were centrifuged at 10,000 rpm for 1 
min to elute the RNA. A second elution was performed using the eluted water and applying 
it again onto the column, followed by a centrifugation at 10,000 rpm for 2 min. Samples 
were stored at -80 ºC until further analysis.  
3.10.3. cDNA synthesis 
Samples were thawed and RNA quality and quantity was determined 
spectrophotometrically using NanoDrop (Thermo Fisher Scientific, Waltham, MA, USA). 
Contaminant genomic DNA was degraded prior to complementary DNA (cDNA) synthesis 
using the kit DNase I - Amplification grade with few alterations to the provided protocol. 
Two micrograms of total RNA of each sample were diluted in DEPC-treated H2O 
(achieving a final volume of 6 µL) and mixed with 2 ng 1.2 kb kanamycin positive control 
RNA. To the previous mixture, 1 µL DNase I (1 U/µL) and 1 µL 10X DNase I Reaction 
Buffer were added. An incubation at 37 ºC for 15 min was performed to allow enzymatic 
reaction. DNase I was then inactivated with 1 µL 25 mM EDTA/tube during incubation at 
65 ºC for 10 min. After this, tubes were spun down to collect condensation and placed on 
ice. The reverse transcription was accomplished using the Omniscript RT Kit, with 
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modifications to the supplied protocol. Nine microliters Reverse Transcription mastermix 
(2 µL 10X Buffer RT, 2 µL dNTP Mix (5 mM each deoxyribonucleotide triphosphate), 4 
µL Oligo dT18 (5 mM), and 1 µL Omniscript Reverse Transcriptase (4 U/µL)) were added 
to each DNase-treated tube and incubated at 37 ºC for 1 h. After enzymatic reaction, cDNA 
samples were spun down and diluted in 380 µL ultrapure H2O. cDNA samples were stored 
at -20 ºC until qRT-PCR reaction.    
3.10.4. qRT-PCR  
Amplification of target cDNA was performed by qRT-PCR using an iCycler iQ5 PCR 
Thermal Cycler (Bio-Rad, Hercules, CA, USA). In brief, wells of a 96-well PCR plate 
(Bio-Rad, Hercules, CA, USA) were filled with 7.5 µL 2X iQ SYBR Green Supermix (100 
mM KCl, 40 mM Tris-HCl, pH 8.4, 0.4 mM each dNTP, 50 U/mL iTaq DNA polymerase, 
6 mM MgCl2, SYBR Green I, 20 nM fluorescein, stabilizers), 3.75 µL forward and reverse 
primer mix (1.5 µM final concentration each primer), and 3.75 µL cDNA sample. 
Additionally, No Template Controls were used, in which instead of cDNA, 3.75 µL 
ultrapure H2O were added. The PCR plate was then carefully sealed and qRT-PCR was 
carried out. For all primer pairs, the conditions for PCR were as follows: initial 
denaturation at 95 ºC for 6 s, followed by 60 cycles comprising denaturation at 94 ºC for 5 
s, annealing at 58 ºC for 15 s, and extension at 72 ºC for 15 s. In addition, the following 
melting program was performed to confirm product specificity: temperature increase from 
68 ºC to 95 ºC, with 0.5 ºC increments for 6 s each. Two independent PCR runs were 
performed per cDNA sample from each biological sample. Raw fluorescence unit (RFU) 
data were obtained from the iQ5 Optical System Software (Bio-Rad, Hercules, CA, USA) 
and were used only when the corresponding PCR reactions were validated by melting 
curve analysis. Determination of gene expression levels was based on the Pfaffl method 
(Pfaffl, 2001). RFU data from baseline-normalized curve fits were used to calculate the 
cycle threshold (Ct) values and average efficiency parameters through Real-Time PCR 
Miner (http://www.miner.ewindup.info/Version2) (Zhao and Fernald, 2005). All genes 
were normalized to the housekeeping gene GAPDH. GAPDH was validated to total RNA 
by comparing GAPDH Ct values with Ct values from the external kanamycin RNA 
transcript, which was directly proportional to total RNA present in the sample. 
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3.11. Data and statistical analysis 
For all assays, at least three independent experiments with replicates were performed. In 
the case of gene expression, two independent experiments were analyzed and two technical 
replicates were performed per PCR run. All data are expressed as mean ± standard 
deviation (SD). The statistical analysis was performed using SigmaPlot for Windows 
version 11.0 (Systat Software Inc., San Jose, CA, USA). The assessment of statistical 
significance between control and SFN-treated groups was performed using one-way or 
two-way analysis of variance (ANOVA), followed by the Holm-Sidak’s test (p<0.05).   
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IV. RESULTS 
 
4.1. Characterization of confluence and cell morphology 
The visualization of control and SFN-treated cells under an inverted microscope revealed 
drastic changes in the overall appearance of cultures exposed to SFN (Figure 6). Adherent 
control cells showed a typical MG-63 fibroblast-like morphology, reaching a confluence of 
70% and 90% after 48 and 72 h, respectively. With the increase of SFN concentration in 
the medium, the confluence of the cultures gradually decreased and the number of 
detached cells increased, for both times. In the culture medium of cells exposed to higher 
doses of SFN (10 and 20 µM), the amount of cell debris was also visibly higher. 
Morphological changes in attached cells were observed within SFN-exposed cultures, 
namely cell enlargement and a rounded shape.  
4.2. Cell viability 
The assessment of SFN-induced cytotoxicity was conducted by the MTT assay and is 
depicted in Figure 7. After 24 h exposure, cell viability was not significantly reduced by 
the concentrations of 5 and 10 µM SFN when compared to control. A decrease in cell 
viability was only observed for the concentration of 20 µM SFN (p<0.05). However, after 
48 h, cell viability was reduced by SFN in a dose-dependent manner (p<0.05). The 
percentage of relative viability decreased in cells exposed to SFN concentrations of 5, 10, 
and 20 µM. Moreover, SFN showed a time-dependent effect. When comparing the effect 
of SFN between both exposure periods, cell viability significantly decreased after a longer 
exposure time for all SFN concentrations. 
4.3. Cell cycle and clastogenicity analysis 
After 24 h exposure, SFN increased the percentage of cells at G2/M phase in a dose-
dependent manner (Figure 8A). This trend was statistically significant for cultures exposed 
to 10 and 20 µM SFN. Simultaneously, after 24 h exposure, all SFN doses decreased the 
percentage of cells at G1/G0 (p<0.05). The 48 h exposure’s results followed the same trend, 
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Figure 6. Microscopic visualization of control and sulforaphane-treated MG-63 cells. Confluence and 
cell morphology of cultures exposed to 0, 5, 10, and 20 µM SFN after 24 and 48 h (100x magnification). Bar 
= 100 µm. 
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Figure 7. Cytotoxic effect of sulforaphane on MG-63 cells. Viability of cells exposed to 5, 10, and 20 µM 
SFN for 24 and 48 h relatively to control (100%). * significant differences between control and SFN-treated 
cells within time (p<0.05). a, b, significant differences between times within a concentration (p<0.05). 
 
 
with all tested SFN concentrations exhibiting greater magnitude of response (Figure 8B). 
After 48 h and compared to control, SFN-treated cultures presented significantly higher 
percentages of cells at G2/M for all tested SFN concentrations. Inversely, for the same 
exposure period, the percentage of cells at G1/G0 phase decreased with every SFN dose 
(p<0.05). As for 24 h exposure, after 48 h exposure, the S phase was not affected by SFN 
(p<0.05). Collectively, these data show a dose-dependent effect of SFN on cell cycle 
distribution. 
Clastogenicity evaluation by the FPCV of the G1/G0 peak showed that SFN didn’t induce 
significant damage when administered for 24 h, as FPCV values from control and 
treatments were similar (Figure 9A). Yet, for the longer exposure period of 48 h, FPCV 
values revealed that SFN exerted a clastogenic effect (p<0.05), given by increasing FPCV 
values in 5, 10, and 20 µM SFN-treated cultures, as shown in Figure 9B. 
4.4. Apoptosis assessment 
When treated for 24 and 48 h with 5 µM SFN, cells didn’t present significant differences in 
the viability status comparing to control. Untreated and 5 µM SFN-treated cultures induced 
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Figure 8. Cytostatic effect of sulforaphane on MG-63 cells. Cell cycle dynamics of MG-63 cells exposed 
to SFN for (A) 24 and (B) 48 h. * significant differences between control and SFN-treated cells (p<0.05). 
 
 
similar percentages of viable, early apoptotic, late apoptotic, and necrotic cells after 24 h 
(Figure 10A). In the meantime, results of 5 µM SFN-treated and untreated cultures after 48 
h showed a resembling trend with no significant differences between their viability status 
(Figure 10B).  
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Figure 9. Sulforaphane-induced clastogenicity. G1/G0 peak FPCV percentage of MG-63 cells exposed to 0, 
5, 10, and 20 µM SFN for (A) 24 and (B) 48h. * significant differences between control and SFN-treated 
cells (p<0.05). 
 
 
Nevertheless, results show induction of apoptosis by the highest SFN doses. As depicted in 
Figure 10, for both 24 (Figure 10A) and 48 h (Figure 10B) exposure times, cultures 
exposed to 10 and 20 µM SFN presented a lower number of viable cells compared to 
control (p<0.05) with a concurrent increase of cells undergoing early and late apoptosis 
(p<0.05). 
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Figure 10. Activation of apoptosis in MG-63 cells exposed to sulforaphane. Percentage of viable, early 
apoptotic, late apoptotic, and necrotic cells after 0, 5, 10, and 20 µM SFN treatment for (A) 24 and (B) 48 h. 
* significant differences between control and SFN-treated cells (p<0.05).  
 
 
Furthermore, the cytotoxicity of SFN does not appear to be associated with the induction 
of necrosis. Necrotic cells were found at similar percentages in every condition for 24 and 
48 h experiments. 
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4.5. Caspase activity assessment 
As pointed earlier, 10 and 20 µM SFN doses were able to induce a significant increase of 
apoptotic cells in treated cultures, and this effect was more pronounced after 48 h. For this 
reason, the enzyme activity of caspase 3, caspase 8, and caspase 9 was only measured in 
cultures exposed to 10 and 20 µM SFN for 48 h. 
Caspase 3 specific activity (Figure 11A) was enhanced with increasing SFN 
concentrations. Nevertheless, this trend was not statistically significant. The assessment of 
caspase 8 showed a slight increase of the specific activity of this enzyme in cultures treated 
with 10 µM SFN and a slight decrease in cultures exposed to 20 µM SFN, when 
comparing to control, but none of the differences were significant (Figure 11B). As 
represented in Figure 11C, caspase 9 specific activity was also enhanced in cultures treated 
with both SFN concentrations. Again, these values were not statistically different from 
caspase 9 activity found in control. 
4.6. Gene expression 
Because of the more pronounced effects obtained in cell cycle distribution after 48 h of 
SFN treatment, expression of genes involved in cell cycle regulation was only quantified in 
cultures exposed to SFN for the described period. Also, cultures exposed to 5 and 20 µM 
SFN were not used in this analysis due to the less intense effects shown in cell cycle 
modulation and the insufficient total amount of RNA obtained after RNA extraction, 
respectively. Consequently, gene expression was measured in control cells vs. 10 µM SFN-
treated cells (Figure 12).  
Expression levels of the analyzed cell cycle genes were in general reduced by SFN, with 
the exception of two genes. After 48 h, expression of CDK2 and CCNB1 in 10 µM SFN-
treated cultures was lower than in control, but without statistical significance. In contrast, 
the same SFN dose significantly downregulated the expression of CHEK1 and CDC25C. 
On the other hand, 10 µM SFN was found to upregulate the expression of CHEK2 and 
CDK1, the latter showing a significant increase in the expression level. 
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Figure 11. Specific activity of two initiator caspases and one executioner caspase after sulforaphane 
treatment. MG-63 cells were treated with 0, 10, and 20 µM SFN and the activity of (A) caspase 3, (B) 
caspase 8, and (C) caspase 9 was measured after 48 h. 
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Figure 12. Relative expression of cell cycle-related genes after exposure to 10 µM sulforaphane for 48 
h. Expression values of CHEK1, CHEK2, CDK1, CDK2, CDC25C, and CCNB1 were normalized to the 
housekeeping gene GAPDH. Data are presented as the expression of each gene in cultures treated with 10 
µM SFN relatively to the expression obtained in untreated cultures. * significant differences between control 
and SFN-treated cells (p<0.05).    
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V. DISCUSSION 
 
Cancer is a complex disease, in part due to the multiplicity of genomic perturbations 
governing the cellular network that allows the survival of cancer cells. Such perturbations 
vary widely between different types of cancer, and even individuals presenting the same 
type of cancer are often found to carry tumors that are driven by their own sets of genomic 
changes. As a result, the effectiveness of current cancer treatment is frequently 
undermined.   
Bone sarcomas, in which OS is comprised, represent 5-10% of children and young adults’ 
malignancies (Skubitz and D'Adamo, 2007). Nevertheless, these sarcomas are somewhat 
rare in an overall view of cancer, accounting for merely 0.2% of all cancers (Greenlee et 
al., 2001). Because of the relative rarity of OS incidence, research on this pathology is 
sometimes hindered by the low number of available study subjects and the poor 
understanding of the biology of this tumor. Additionally, current treatment options for OS 
seem to fail in achieving successful survival rates and induce aggressive toxicity (Bacci et 
al., 2003; Patel et al., 2004; Duffaud et al., 2012; Ebb et al., 2012). 
SFN, a naturally occurring ITC, has evidenced to modulate several key signaling pathways 
in different types of cancer, both in vitro and in vivo. Induction of apoptosis and blockage 
of cell cycle progression in cancer cells are two well-established SFN properties that make 
this phytochemical a promising agent in cancer therapy (Fimognari and Hrelia, 2007). 
Considering the above mentioned, this dissertation aimed to investigate the potential of 
SFN as a chemotherapeutic agent for OS, evaluating its cytotoxicity in an in vitro human 
OS model and clarifying some of the molecular mechanisms leading to it. MG-63 cells 
were exposed to 5-20 µM SFN for 24 and 48 h, after which several parameters were 
assessed. The range of SFN doses was selected based on the literature.   
Results show that SFN induced a cytotoxic effect on MG-63 cells, promoting a decrease in 
cell viability in a dose- and time-dependent manner. Several studies support a 
magnification of SFN cytotoxicity with higher doses and longer exposures in different 
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human cancer cells, but this effect appears to be highly dependent on the cell type 
(Misiewicz et al., 2005; Yeh and Yen, 2005; Chaudhuri et al., 2007; Jin et al., 2007).   
The cell cycle dynamics of MG-63 cells after SFN treatment was also inquired through 
DNA content analysis by flow cytometry. For both exposure periods, the S phase presented 
non-significant alterations; contrarily, SFN is shown here to diminish the number of cells 
in G1/G0 phase and concurrently raise the G2/M phase cell population, again in a dose-
dependent manner. This accumulation of cells with DNA content = 4N shows that SFN 
induces a G2/M phase arrest in this human OS model. As the majority of cancer cell lines 
affected by SFN, the progression of MG-63 cell cycle was blocked at G2/M phase and for 
that some mechanisms have been unveiled.  
The G2/M arrest is commonly a consequence of DNA damage and this arrest typically 
enables the cell machinery to repair the DNA lesions, thereby maintaining the genome 
integrity and preventing the propagation of defective DNA to daughter cells. This is 
generally achieved by the activation of the G2/M DNA damage checkpoint through the 
recognition of DNA damage by molecular sensors that activate a cascade of kinases; the 
most downstream ones, in turn, directly target cell cycle key controllers, blocking the 
transition to mitosis (Medema and Macurek, 2012). Macip and colleagues reported 
induction of a reversible G2/M arrest by sublethal doses of ROS via Chk1 phosphorylation 
(Macip et al., 2006) and, actually, production of ROS has been correlated with SFN-
induced cell cycle arrest at G2/M. Mitochondrial DNA deficient Rho-0 variants of LNCap 
and PC-3, two human prostate cancer cell lines, were shown to be more resistant to several 
SFN effects, including G2/M cell cycle arrest, than the corresponding wild-type cells, with 
mitochondria-derived ROS playing a key role in the initiation of SFN cytotoxicity (Xiao et 
al., 2009); another study supports ROS-mediated blockage of G2/M transition in prostate 
cancer cells exposed to SFN (Cho et al., 2005). Interestingly, data generated by our group 
also showed that the increase in ROS production is correlated with G2/M cell cycle arrest 
in MG-63 after SFN treatment (Costa et al., 2012). Remarkably, the generation of ROS 
induced by SFN appears to be tumor cell specific (Antosiewicz et al., 2008).  
Matsui and collaborators found an upregulation of p21Cip1 in MG-63 after SFN treatment 
that contributed to G2/M blockage (Matsui et al., 2007) and the same was observed in U2-
OS, another OS cell line (Kim et al., 2011). These results reinforce the potential of SFN as 
a chemotherapeutic agent for OS, since they reveal that the expression of p21Cip1, a CKI 
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whose expression is tightly regulated by the transcription factor p53, is modulated by SFN 
even when p53 is inactivated (a common alteration in OS).      
If the DNA damage is reparable, the G2/M checkpoint is deactivated and cells can progress 
to mitosis after restoring the DNA integrity. Nevertheless, it has also been proposed that 
SFN may induce ROS-independent G2/M arrest by disruption of tubulin polymerization 
and spindle assembly. A correct segregation of chromosomes during mitosis requires 
formation of the mitotic spindle, which includes polymerization of α- and β-tubulin 
heterodimers into microtubules (Walczak and Heald, 2008). Mi and collaborators 
demonstrated that in A549, a carcinomic human alveolar basal epithelial cell line, SFN 
directly targets α- and β-tubulin inducing conformational changes (probably due to 
covalent bonding to cysteine residues), which results in microtubules disruption and 
tubulin polymerization inhibition (Mi et al., 2008). Perturbations in microtubules dynamics 
were also presented in other SFN reports (Jackson and Singletary, 2004a; Jackson and 
Singletary, 2004b; Jackson et al., 2007; Azarenko et al., 2008) and were always associated 
with G2/M arrest. This effect was confirmed by recent data from our group showing that 
SFN triggers microtubules disruption in MG-63 cells (unpublished observations).  
The variation in DNA content measured by the FPCV of the G1/G0 peak can be used as 
diagnosis for clastogenic damage within a cell population. The dispersion of nuclear DNA 
content measured by this flow cytometric parameter reflects chromosomal perturbations 
(e.g., chromosome breakage and reattachment, loss of chromosome fragments) that result 
in unequal distribution of DNA in the daughter cells and magnification of the genomic 
destabilization by further divisions (Misra and Easton, 1999). The significant increase of 
the FPCV values for all SFN doses, after 48 h of treatment, suggests that SFN leads to 
clastogenic damage in MG-63 cells exposed for longer periods to this ITC. Different 
genotoxic effects of SFN have already been demonstrated. DNA single (Sestili et al., 2010) 
and double (Singh et al., 2004b; Sekine-Suzuki et al., 2008; Sestili et al., 2010) strand 
breaks were found in different transformed and non-transformed cell lines after treatment 
with SFN. In fact, DNA breaks were previously detected in SFN-treated MG-63 cells in a 
dose-dependent manner after 48 h exposure, but the type of breaks (single or double) 
remains unclear (Pinto, 2011). Moreover, micronuclei and nucleoplasmic bridges may 
arise during nuclear division from lagging whole chromosomes/acentric chromosome 
fragments and from dicentric chromosomes caused by misrepair of double strand DNA 
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breaks/telomere end fusions, respectively (Fenech, 2007). Exposure to SFN increases the 
frequency of such nuclear alterations in MG-63 cells (Remédios et al., 2012). Yet, and as 
for other SFN effects, the induction of micronuclei appears to depend on the cell type, 
dose, and culture conditions, since SFN is also able to prevent micronuclei formation 
induced by selected mutagens (Fimognari et al., 2005). Taking into account the previously 
discussed and the results from the flow cytometric analysis, the G2/M arrest in this OS 
model was probably activated by SFN-induced DNA damage.  
Apoptosis plays a vital role in the maintenance of tissue homeostasis. Depending on the 
extent of the DNA damage that triggers cell cycle arrest, cells can re-enter cell cycle 
progression (as stated before) or, in case DNA damage is not reparable, cells can activate 
the apoptotic machinery and die through programmed cell death (Medema and Macurek, 
2012). To examine whether apoptosis could be involved in the loss of cell viability driven 
by SFN, the FITC Annexin V assay was performed. Data indicate that the lowest SFN dose 
(5 µM) was not able to induce apoptosis in MG-63, either for 24 or 48 h treatments. 
Nevertheless, for the same exposure periods, 10 and 20 µM SFN significantly reduced the 
viability within the cell populations and, at the same time, increased cell death through 
apoptosis, as shown by the higher number of MG-63 cells with early and late apoptotic 
characteristics. Kim and colleagues used the same range of SFN doses and found apoptotic 
cell death in another OS cell line, evidenced by the FITC Annexin V assay and the 
apoptotic characteristic ladder pattern of DNA fragmentation, which was confirmed by the 
proteolytic cleavage of the caspase 3 substrates poly (ADP-ribose) polymerase (PARP) and 
inhibitor of caspase-activated DNase (ICAD) (Kim et al., 2011), supporting the results of 
this dissertation. Although the molecular basis of apoptosis in MG-63 cells was not 
identified, several in vitro and in vivo studies report SFN-induced apoptosis through a 
multitude of mechanisms: upregulation of gene and/or protein expression of pro-apoptotic 
factors, as Bax (Gamet-Payrastre et al., 2000; Fimognari et al., 2002; Singh et al., 2004a; 
Choi and Singh, 2005; Yeh and Yen, 2005; Devi and Thangam, 2012), Bak (Choi and 
Singh, 2005), and p53 (Fimognari et al., 2002; Park et al., 2007; Devi and Thangam, 
2012); downregulation of protein expression of anti-apoptotic factors, as X-linked inhibitor 
of apoptosis protein (XIAP) (Choi and Singh, 2005; Choi et al., 2007), Bcl-2 (Jackson and 
Singletary, 2004b; Singh et al., 2004a; Yeh and Yen, 2005; Park et al., 2007; Pledgie-
Tracy et al., 2007; Hamsa et al., 2011; Sharma et al., 2011; Devi and Thangam, 2012; 
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Wang et al., 2012), and Bcl-XL (Yeh and Yen, 2005; Park et al., 2007); and upregulation 
of protein expression of intrinsic apoptotic pathway mediators, as Apaf-1 (Choi and Singh, 
2005; Choi et al., 2007). Noteworthy, the cytotoxicity exerted by SFN in MG-63 was not 
associated with necrosis, other type of cell death considered less controlled than apoptosis 
and characterized by cellular swelling, release of intracellular components into the 
microenvironment, and induction of inflammatory response (de Bruin and Medema, 2008). 
Taken together, these results support the aspects described in the qualitative 
characterization of MG-63 cells after SFN treatment. Regarding the loss of confluence, 
control cells proliferated normally, whereas SFN-treated cells suffered a blockage in cell 
cycle, preventing a regular growth rate. Apoptosis also contributed to this outcome, as well 
as to the increased amount of detached cells and cell debris in the medium of cultures 
exposed to 10 and 20 µM SFN, the same doses that succeed in the activation of the 
apoptotic program in these cells. Microscopic visualization also revealed morphological 
changes (enlargement and rounded shape) in attached cells of treated cultures. Chauduri 
and collaborators reported the same cell shape in another monolayer cancer cell line upon 
SFN treatment (Chaudhuri et al., 2007). Targeting of α- and β-tubulin by SFN can justify 
the changes in the cell aspect. These proteins are components of the microtubule 
cytoskeleton and, as referred before, SFN directly binds to them and induces 
conformational changes that lead to the disruption of microtubules and impairment of 
tubulin polymerization (Jackson et al., 2007); collapse of the microtubule cytoskeleton was 
associated with acquisition of a rounded shape in other cells upon SFN exposure (Mi et al., 
2008). In addition, a proteomic analysis of A549 cells treated with SFN revealed that actin, 
other tubulin chains, vimentin, tropomyosin, and desmin (constituents of different 
cytoskeletal structures) are potential protein targets of this ITC (Mi et al., 2011). Thus, a 
cytoskeleton rearrangement of MG-63 cells due to SFN-microtubule proteins interaction 
may be the foundation for the observed morphological alterations of these OS model. 
The effect of SFN on apoptosis induction prompted the next series of experiments wherein 
an attempt to determine the triggered apoptotic pathway(s) was made. Caspase 8 and 
caspase 9 were chosen as representatives from the extrinsic and intrinsic apoptotic 
pathways, respectively, as they initiate the corresponding apoptotic pathways, and their 
activity was measured. The activity of caspase 3, the first executioner of the caspase 
cascade that leads to apoptosis and substrate of caspases 8 and 9, was also explored. Our 
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data do not clearly demonstrate the activated apoptotic pathway. Although results are 
indicative of an increment of caspase 9 activity with 10 and 20 µM SFN and the same 
effect for caspase 8 activity after 10 µM SFN when compared to control, the lack of 
statistical significance in the obtained differences restrain any assumptions on the subject. 
Data from caspase 3 assessment also points to a boost in its activity by the tested SFN 
doses, but once more not statistically significant However, these negative results must be 
interpreted cautiously, because a substantial variability in the caspase activity of samples 
from the same condition was observed in every caspase assessed (as shown by the high SD 
values), which can cover a difference in the activity of these enzymes between untreated 
and treated cultures when one actually exists. Moreover, the profile of caspase 3 activity, 
even though not showing statistical magnitude, is sustained by the results from the FITC 
Annexin V assay that demonstrate undoubtedly apoptotic cell death. As for other human 
cancer cell lines, SFN-induced apoptosis seems to occur through different pathways. 
Activation of caspase 8 is reported in pancreatic cancer cells (Pham et al., 2004) and 
Barrett’s adenocarcinoma (Qazi et al., 2010), while procaspase 9 cleavage or caspase 9 
activation occur in different colon cancer cell lines (Pappa et al., 2006) and 
medulloblastoma (Gingras et al., 2004) upon SFN administration. Also, the apoptotic 
pathway induced by SFN can vary within a cancer type, as Pledgie-Tracy and team found 
in different breast cancer cell lines (Pledgie-Tracy et al., 2007). On the other hand, intrinsic 
and extrinsic pathways are not exclusively activated in apoptosis caused by SFN. Studies 
suggest that SFN is able to activate both mitochondria- and death receptor-mediated 
pathways in the same cell line (Singh et al., 2004a; Nishikawa et al., 2009; 
Balasubramanian et al., 2011). Alternatively, a caspase 12-dependent apoptosis is possible 
to occur as well, as determined by Karmakar and colleagues in SFN-treated glioblastoma 
cells (Karmakar et al., 2006). In the case of MG-63 cells, more experiments are required to 
better understand the cause of the variability found across this work and to clarify whether 
SFN-induced apoptotic death is driven by caspase 8, caspase 9, both, or even other 
alternative caspases. 
Next, to elucidate if a different expression of cell cycle-related genes could be involved in 
the cell cycle arrest induced by SFN in the used OS model, qRT-PCR analysis of G2/M key 
regulators was performed. The completion of G2 phase and progression through mitosis 
requires activation of Cdk1/cyclin B1 complex, also known as maturation-promoting factor 
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(MPF), in which the kinase activity that triggers the access to mitosis relies on Cdk1 
(Lindqvist et al., 2007). Cyclin B1 is the regulatory element of MPF and without it the 
complex lacks activity. After SFN treatment, CDK1 (coding for Cdk1) expression levels 
significantly increased. In contrast, levels of CCNB1 (coding for cyclin B1) suffered a 
slight reduction that was not considered statistically significant. Nevertheless, a 
considerable variability was found in the expression of this gene and the possibility that 
SFN plays an inhibitory role in it shouldn’t be excluded. Considering this, mitotic entry 
could have been hindered through the direct downregulation of cyclin B1 by SFN, which is 
supported by other studies (Singh et al., 2004b; Balasubramanian et al., 2011), including in 
OS cells (Kim et al., 2011).  
Furthermore, the activity of Cdk1 is negatively regulated by phosphorylation (e.g., Wee1 
and Myt1 kinases), which can be reversed by the phosphatase Cdc25C (Medema and 
Macurek, 2012). Expression levels of CDC25C in SFN-treated cells showed a significant 
decrease relatively to untreated ones, in this work as in others (Singh et al., 2004b; 
Herman-Antosiewicz et al., 2007), suggesting an important role for Cdc25C depletion, and 
hence Cdk1/cyclin B1 inactivation, in SFN-induced G2/M cell cycle arrest. Therefore, the 
potential higher expression of Cdk1 at the protein level can be overcome through the 
downregulation of Cdc25C that leads to an accumulation of phosphorylated (inactive) 
Cdk1.  
The G2/M checkpoint-mediated cell cycle arrest in response to DNA damage is at least in 
part established through inhibition of Cdc25C activity by the serine/threonine protein 
kinases Chk1 and Chk2 (Boutros et al., 2007); these kinases integrate signals from the 
DNA damage sensors Ataxia telangiectasia mutated (ATM) and ATM- and Rad3-related 
protein (ATR). For this reason, expression levels of CHEK1 and CHEK2 encoding Chk1 
and Chk2, respectively, were quantified. SFN had a negative effect on the expression of 
CHEK1. Contrarily, CHEK2 presented a slightly higher level of mRNA upon SFN 
treatment, but not significant. These results suggest that inhibition of Cdc25C (already less 
expressed in SFN-treated MG-63 cells) was prompted mainly by Chk2, as it presented at 
least a constant level of expression. The role of Chk2 in SFN-induced G2/M blockage was 
noticed in human prostate cancer cells and was confirmed by an increase in the resistance 
to this effect in the same cells transfected with Chk2-specific small interfering RNA 
duplexes (Singh et al., 2004b).  
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In addition, the role of p53-independent G2/M arrest in MG-63 was investigated. The MG-
63 cell line carries rearrangement of the p53 gene and low levels of transcripts are 
produced, which results in virtually no expression of wild-type p53 in this cell line 
(Chandar et al., 1992; Ottaviano et al., 2010). Since null mutations of CDK2 have been 
found associated with defective G2/M arrest (Chung and Bunz, 2010), the CDK2 gene 
expression was also investigated. As for the case of cyclin B1 gene, MG-63 cells exposed 
to SFN presented lower, although not significantly lower, levels of Cdk2. However, given 
the high variability in gene expression observed, it is not conclusive whether this gene is 
downregulated upon exposure to SFN. 
Figure 13 shows the alterations in gene expression found across the present work that may 
be involved in the G2/M cell cycle arrest obtained after exposure of MG-63 cells to 10 µM 
SFN. These last results concerning gene expression should be cautiously interpreted due to 
different reasons: a) data were obtained from two independent experiments; b) some gene 
profiles show high SD values that may be hiding existing differences between treated and 
untreated cells; and c) the level of gene expression does not always relate with the level of 
protein expression or protein activity. 
 
DISCUSSION 
 56 
Key:
Kinase
Phosphatase
Cyclin
Direct Stimulatory 
Modification
Direct Inhibitory 
Modification
Significant Overexpression
Significant Underexpression
Non Significant Underexpression
Non Significant Overexpression
DNA Damage
 
 
Figure 13. Sulforaphane-induced changes in gene expression of MG-63 that may contribute to 
activation of G2/M DNA damage checkpoint. Adapted from Cell Signaling Technology Inc. (2010) 
(http://www.cellsignal.com/reference/pathway/Cell_Cycle_G2M_DNA.html).     
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VI. CONCLUSION AND FUTURE 
PERSPECTIVES 
 
The present study supports the cytotoxic effect of SFN already described for several 
tumors and provides evidences that SFN should be considered a promising candidate for 
OS treatment. SFN caused visible cell morphological changes, cell cycle arrest at G2/M 
phase, and apoptosis in the human OS model MG-63, the last two events most likely 
triggered by SFN-induced DNA damage. Beyond that, preliminary results show that cell 
cycle arrest was mainly mediated by Chk2, CDC25C downregulation, and probably 
CCNB1 as well as CDK2 downregulation. 
Nevertheless, the effect of SFN on OS should be further investigated in order to expand 
our knowledge about the molecular mechanisms underlying these effects. The analysis of 
expression profiles of other genes, such as apoptotic-related genes, would be important to 
fully characterize cellular events reported in the present dissertation. Also, protein 
quantification (e.g., Western blot) would be very interesting to perform, with particular 
attention to the different protein forms (activated/inactivated, 
phosphorylated/dephosphorylated, etc.), enabling a comparison with the gene expression 
profile and a better understanding of the signaling pathways that lead to certain events 
induced by SFN. New chemotherapeutic agents for OS (and other cancers) should display 
a sufficiently large therapeutic window and at the same time spare normal cells. A 
comparative study with different human OS cell lines (e.g., Saos-2, U2-OS, HOS, NOS-1, 
etc.) and a normal osteoblast cell line is advisable to determine whether SFN effects are 
tumor selective and whether it exerts a similar cytotoxicity in a broad variety of tumor 
phenotypes. Lastly, a great deal of attention must be given to the fact that SFN is able to 
induce clastogenicity. Such effect should be carefully considered in an already inherently 
unstable genomic context as cancer cells.       
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